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SelectivityWith the success of protein kinase inhibitors as drugs to target cancer, there is a continued need for
new kinase inhibitor scaffolds. We have investigated the synthesis and kinase inhibition of new
heteroaryl-substituted diazaspirocyclic compounds that mimic ATP. Versatile syntheses of substituted
diazaspirocycles through ring-closing metathesis were demonstrated. Diazaspirocycles directly linked
to heteroaromatic hinge binder groups provided ligand efﬁcient inhibitors of multiple kinases, suitable
as starting points for further optimization. The binding modes of representative diazaspirocyclic motifs
were conﬁrmed by protein crystallography. Selectivity proﬁles were inﬂuenced by the hinge binder group
and the interactions of basic nitrogen atoms in the scaffold with acidic side-chains of residues in the ATP
pocket. The introduction of more complex substitution to the diazaspirocycles increased potency and
varied the selectivity proﬁles of these initial hits through engagement of the P-loop and changes to the
spirocycle conformation, demonstrating the potential of these core scaffolds for future application to
kinase inhibitor discovery.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Protein kinases play a vital role in signal transduction path-
ways involved in cellular proliferation and survival, and are often
implicated in deregulated signaling leading to cancer.1–3 The
development of protein kinase inhibitors to target the underlying
mechanisms of cancer cell growth and survival has resulted in
several licensed treatments.4,5 The design of speciﬁc targeted
inhibitors is important, but preclinical research and clinical expe-
rience also shows that inhibitors with multi-target proﬁles can be
effective through the ability to inhibit multiple signaling events
simultaneously.6–8 There is a continued need for new protein ki-
nase inhibitor scaffolds, particularly those that can act as plat-forms for modiﬁcation to vary selectivity proﬁles.9 Many
inhibitors have been designed to target the conserved ATP cofac-
tor binding site, and both highly speciﬁc and multi-targeted li-
gands can arise from this approach. Type I ATP-competitive
inhibitors recognize the active conformation of kinases, and typi-
cally possess a core heteroaromatic ring system that forms hydro-
gen bonds to the hinge-peptide of the kinase in an analogous
fashion to ATP. Interactions in other regions of the kinase active
site can be introduced through extension of the core scaffold along
appropriate vectors.4,10–12
We have previously described compounds such as 4-(4-chloroben-
zyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine (1, Fig. 1)
which selectively inhibits PKB over other kinases within the AGC
family.13,14 Compound 1 closely resembles the pharmacophore
deﬁned by ATP bound to the kinase (Fig. 1A). The selectivity of 1
was dependent upon the positioning of a basic primary amine in
the ribose pocket, where it could interact with a glutamic acidic
residue in PKB and backbone carbonyl functionality, as well as
exploiting a close contact with a methionine side chain.13 3-Ami-
nopyrrolidine-based PKB inhibitors targeting these structural fea-
tures have also been reported.15
We speculated that incorporation of the pendant primary amine
into a second, spirocyclic ring could provide new scaffolds for ATP-
competitive kinase inhibition, and that the inhibition proﬁles could
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Scheme 1. 4-Benzyl-4-aminopiperidine 3 and N-protected, unsubstituted [4.5]-
and [5.5]-diazaspirocyclic scaffolds 4–10. Reagents and conditions: (a) (i) Cbz-Cl,
NEt3, CH2Cl2, 65–82% then (ii) 4 M HCl in dioxane, MeOH, 0–4 C, 80–100%.
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Figure 1. (A) Overlay of ATP (cyan carbons; PDB 1Q24) and 1 (green carbons, PDB
2VO6) in the bound conformations observed in the active sites of PKB–PKA chimeric
proteins; (B) Design of diazaspirocyclic scaffolds to fulﬁl the pharmacophore
deﬁned by ATP and 1.
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Diazaspirocycles have been proposed as generally useful scaffolds
for drug design,17 and these scaffolds incorporate a potentially
favourable solubilising element into the core of the inhibitors.18
Compared to more typical, planar kinase inhibitor motifs, the rigid
spirocyclic structures increase the three-dimensional shape of
molecules where they are present, which may be associated with
better physicochemical properties.19,20 Simple, unsubstituted ali-
phatic diazaspirocycles have been incorporated into kinase inhibi-
tors as peripheral substituents in the patent literature, but these
are most often seen as minor examples in much broader surveys
of substituent amines.21 The use of diazaspirocycles as core scaf-
folds to explore binding within the ATP-pocket, and the effect of
substitution of these scaffolds on the selectivity proﬁle of kinase
inhibitors, has not been extensively detailed,15,22 or has involved
the embedding of the spirocycles in non-aliphatic fused structures,
such as spiroindolines.15,23
We therefore investigated the synthesis and kinase inhibition
of heteroaryl-substituted diazaspirocycles following the general
design 2 (Fig. 1B) capable of delivering a nitrogen atom into the
ribose pocket of the ATP binding site, while orienting a heteroaro-
matic group to interact with the hinge peptide, and providing a
platform for elaboration towards the P-loop. Unsubstituted diaza-
spirocyclic scaffolds were chosen to vary the position of the basic
nitrogen relative to the point of attachment to the hinge-binding
group. To each of the scaffolds, purin-6-yl13 and isoquinolin-5-sul-
fonamide24 kinase heteroaromatic hinge binders previously exem-
pliﬁed in AGC kinase inhibitors were attached, chosen to vary thedegree and orientation of contact between the ligand and the
hinge-peptide, and the position of the spirocycles. Following
assessment of these compounds against a representative panel of
protein kinases, versatile synthetic routes were developed to intro-
duce aromatic or polar functionality at two positions of a [5.5]-
diazaspirocycle purine derivative with inhibitory activity, and thus
to study the effect on the inhibition proﬁles with these new substi-
tuted diazaspirocycles.
2. Synthetic chemistry
The 4-amino-4-benzylpiperidine scaffold 3 was made as a non-
spirocyclic comparator, following our previously reported synthe-
sis25 (Scheme 1). Jenkins et al. have described robust syntheses
of the [5.5]-diazaspirocycle 4, through ring-closing metathesis
(RCM), and [4.5]-diazaspirocycle 5, through a bromine-mediated
cyclisation, both starting from 1-benzylpiperidine-4-one.17 Com-
mercially available [5.5]-diazaspirocycles 6, 7 and [4.5]-diazaspiro-
cycle 8 provided variations in the positions of the nitrogen atoms.
Compounds 5 and 6were subjected to a protecting group exchange
to generate scaffolds 9 and 10with the basic nitrogen translocated.
Heteroaromatic groups were attached to the scaffolds 3–10
through SNAr reactions with 6-chloropurine13 and sulfonylation
with isoquinoline-5-sulfonyl chloride.24 N-deprotection under
acidic conditions gave compounds 11–26 (Table 1). The unpro-
tected 4-amino-4-benzylpiperidine 3 reacted regioselectively at
the more nucleophilic piperidine nitrogen with 6-chloropurine
and isoquinoline-5-sulfonyl chloride to give 11 and 19, respec-
tively, as conﬁrmed by NMR and MS-fragmentation analysis. With
the exception of 21, diazaspirocycles were introduced with mono-
N-protection to avoid poor regioselectivity in the couplings. 3-Aza-
spiro[5.5]undecane, 1-oxa- and 2-oxa-9-azaspiro[5.5]undecane
purine derivatives 27–29 were prepared using similar methods
(Scheme 2).
The purine [5.5]-diazaspirocycle 12 was chosen for synthetic
modiﬁcation to introduce a selection of hydrophobic and polar
functional groups to the C-3 and C-4 positions of the 1,9-diazaspi-
ro[5.5]undecane. Compound 3017, an intermediate in the synthesis
of 4, was hydroborated with 9-BBN to give a chromatographically
separable 1:1 mixture of alcohols 31 and 32 after oxidation
(Scheme 3). Transfer hydrogenation was found to be optimum
for the N-benzyl deprotection, as 33 and 34 failed to react under
standard hydrogenation conditions. Introduction of the purine
and isoquinoline sulfonamide substituents followed by N-Boc
deprotection gave compounds 33–36.
Table 1
Synthetic conditions and yields for the coupling and N-deprotection of the 4-benzyl-4-aminopiperidine 3 and spirocycles 4–10 (R1) with the hinge binding heteroaromatic groups
(R2).
11
(72%)a
12
(71%)a, b
13
(68%)a,c
14
(61%)a,d
15   
(53%)a, b
16 
(60%)a, b
17      
(48%)a, b
18        
(7%)a, b
19
(33%)e
20    
(60%)e, b
21
(17%)e, f
22
(14%)e, d
23
(29%)e, b
24   
(52%)e, b
25       
(71%)e, b
26        
(2%)e, b
a6-Chloropurine, NEt3, nBuOH, 100 C.
b4 M HCl in dioxane, MeOH, rt.
c6 M HCl, microwave irradiation, 100 C; 15 min.
dCF3CO2H, 40 C, 24 h.
eIsoquinolin-5-yl sulfonyl chloride, NEt3, CH2Cl2.
fPrepared by sulfonylation of the unprotected diamine intermediate.
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Scheme 3. Synthesis of compounds 33–36 containing racemic 1,9-diazaspi-
ro[5.5]undecan-3-ol and 1,9-diazaspiro[5.5]undecan-4-ol scaffolds. Reagents and
conditions: (a) (i) 0.5 M 9-BBN, THF, 0 C to reﬂux, (ii) 1 M NaOH, 15% H2O2; (b)
separation by chromatography, 46 31%, 47 32%; (c) HCO2NH4, 10% Pd/C, MeOH,
reﬂux, 86–100%; (d), 6-chloropurine, NEt3, nBuOH, 100 C, reﬂux, 45–46%; (e),
isoquinolin-5-yl sulfonyl chloride, NEt3, CH2Cl2, 37–42%; (f) 4 M HCl in dioxane,
MeOH, 80–86%.
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Scheme 2. Preparation of 3-azaspiro[5.5]undecane, 1-oxa- and 2-oxa-9-azaspi-
ro[5.5]undecane derivatives 27–29. Reagents and conditions: (a) 6-chloropurine,
NEt3, nBuOH, 100 C, 14–65%.
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stituents to the 1,9-diazaspiro[5.5]undecane scaffold (Scheme 4).
4-Amino-4-allylpiperidine 3717 was acylated with acryloyl chlo-
ride to give a bis-alkene, which underwent RCM with Grubbs I cat-
alyst and Ti(iPrO)4 as an additive26 to form the unsaturated lactam
38. 1,4-Addition of cuprates introduced phenyl and benzyl groups
to the C-4 position of 38.27 The success of these reactions depended
on the copper (I) source and the concentration of the cuprate, with
CuBr.SMe2 and 1 M concentration in THF identiﬁed as optimal for
the formation of the 1,4-addition products 39 and 40. Compounds
39 and 40 were reduced using an excess of LiAlH4, followed by N-
benzyl deprotection to give the diamine intermediates in good
yields. SNAr and sulfonylation reactions of the diamines were reg-
ioselective for reaction at the less hindered piperidine nitrogen, but
were inefﬁcient. While purines 41 and 42 were isolated after chro-
matography, the corresponding isoquinoline compounds were not
obtained.
An alternative RCM strategy was investigated to install substit-
uents to position C-3 of the 1,9-diazaspiro[5.5]undecane.26,28
Amine 37 was acylated with freshly prepared 2-benzylacryloyl
chloride (Scheme 4).29 The RCM using Grubbs I catalyst was poorly
reproducible, but Hoveyda-Grubbs II catalyst gave the tri-substi-
tuted lactam 43 reliably in good yield (66%). Filtration through
amine-functionalised ion-exchange resin was found to be an effec-
tive method for the removal of ruthenium residues following the
RCM.30 Hydrogenation of 43 reduced the alkene while keepingthe benzyl protecting groups intact. The lactam was reduced using
excess LiAlH4, followed by N-debenzylation to give 44 in good
yield. A regioselective SNAr reaction with 6-chloropurine gave
compound 45.
When applying the above route to introduce phenyl substitu-
tion at C-3, the RCM reaction using Hoveyda-Grubbs II catalyst
with Ti(iPrO)4 generated 46 in low yields with unpredictable reac-
tion times of between 24–72 hours. This was surprising, as phenyl-
substituted dienes are reported to be metathesised efﬁciently.31
The RCM was attempted using the less sterically hindered Grubbs
N
Bn
NBn
O
Ph
N
H
NH
Ph
N
NH
N
N NH
N
Ph
N
Bn
NBn
O
Bn
N
H
NH
Bn
N
Bn
NBn
N
Bn
NBn
CO2Me
N
NH
CO2Me
N
N NH
N
37
46 47
48
43 44
4950
51
f, k
eh, c, d
N
Bn
NBn
O
N
Bn
NBn
OR
N
NH
R
N
N NH
N
3839 R = Ph
40 R = Bn
41 R = Ph
42 R = Bn
a
bc, d, e
f, g
h, i, j
g
N
NH
N
N NH
N
Bn
45
l
d, e
N
Bn
NBn
OR
p, q
N
NH
OR
N
N NH
N
54 R= -NHMe
55 R= -NMe2
56 R= morpholin-4-yl
57 R = -NHMe
58 R = -NMe2
59 R = morpholin-4-yl
N
NH
CO2H
N
N NH
N
N
Bn
NHBn
CO2Me
e
m
N
NH
CH2OH
N
N NH
N
n o
52 53
Scheme 4. Preparation of phenyl-, benzyl-, carboxylate- and carboxamide-substituted racemic 1,9-diazaspiro[5.5]undecane derivatives 41, 42, 45, 51–53 and 57–59.
Reagents and conditions: (a) (i) Acryloyl chloride, DMAP, Et3N, CH2Cl2, 91%; (ii) Grubbs I catalyst, Ti(iPrO)4, CH2Cl2, reﬂux, 76%; (b) CuBrSMe2, PhMgBr or BnMgBr, TMSCl, THF,
40 C to 78 C, 84–95%; (c) LiAlH4, THF, 50 C, 63–80%; (d) 10% Pd/C, H2, MeOH, 50 C, 82–100%; (e) 6-chloropurine, Et3N, nBuOH, 100 C, 23–43%; (f) 2-phenyl- or 2-
benzylacryloyl chloride, DMAP,Et3N or EtNiPr 2, CH2Cl2 49–84%; (g) Hoveyda-Grubbs II catalyst, Ti(iPrO)4, CH2Cl2, 40 C, 66%; (h) 10% Pd/C, H2, EtOH, HCl, 30 C, 100%; (i) 10%
Pd/C, H2, MeOH, HCl, 40 C, 60–94%; (j) Dichloro[1,3-bis(2-methylphenyl)-2-imidazolidinylidene](2-isopropoxy-phenylmethylene)ruthenium(II), toluene, 80 C, 76–82%; (k)
1 M LiAlH4, AlCl3, THF, 50 C, 55%; (l) 10% Pd/C, (HCO2)NH4 1,2-dimethoxyglycol, 16%; (m) methyl 2-(bromomethyl)acrylate, K2CO3, MeCN, 95%; (n) LiOH, THF:MeOH:H2O
(3:2:1), 27%; (o) (i) LiOH, THF:MeOH:H2O (3:2:1); (ii) HATU, DIPEA, DMF, R1R2NH, 49–94% (2 steps); (p) 10% Pd/C, H2, iPrOH, AcOH, 100%.
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(2-isopropoxyphenylmethylene)ruthenium (II), which has been re-
ported to give increased activity in the formation of trisubstituted
oleﬁns,32 and 46 was isolated in good yield (76%). Hydrogenation
of 46 removed the double bond, but in contrast to lactam 43, the
N-benzyl protecting group of the piperidine ring was also cleaved.
Reduction of the lactam was difﬁcult, with LiAlH4, DIBAL-H, BH3-
THF or 9-BBN giving either unreacted starting material or mix-
tures of starting material and the partially reduced hemiaminal.
We speculated that the 3-phenyl substituent adjacent to the lac-
tam carbonyl was sterically impeding nucleophilic attack. There-
fore, the smaller and more reactive reducing agent AlH3 was
prepared in situ from LiAlH4 and AlCl3,33 and gratifyingly gave full
reduction of the amide. Removal of the remaining N-benzyl group
was achieved by transfer hydrogenolysis to give the diamine
47. The regioselective SNAr reaction of 47 with 6-chloropurine
yielded 48.
To prepare the C-3 ester derivative of the 1,9-diazaspi-
ro[5.5]undecane, intermediate 37 was alkylated using methyl 2-
(bromomethyl)acrylate to give bis-alkene 49 in good yield
(Scheme 4). The RCM of 49 was ﬁrst attempted with Grubbs I cat-
alyst in the presence of pTsOH, according to a method outlined by
Prusov and Maier28 but no conversion of the starting material was
observed with this catalyst, nor with Hoveyda-Grubbs II catalystand Ti(iPrO)4. However, dichloro[1,3-bis(2-methylphenyl)-2-imi-
dazolidinylidene](2-isopropoxyphenylmethylene) ruthenium (II)
gave full conversion of the bis-alkene to the cyclised product 50
in good yield. The spirocycle 50 was hydrogenated to reduce the
alkene and remove the N-benzyl protecting groups. A subsequent
SNAr reaction with 6-chloropurine gave 51.
The ester 51 was converted to the carboxylic acid 52 and
hydroxymethyl derivative 53 (Scheme 4). The methyl, dimethyl
and morpholine amides 54–56 were prepared by hydrolysis of
the ester 51 to the lithium salt of the acid followed directly by
amine couplings. Exhaustive hydrogenation removed the N-benzyl
protecting groups and reduced the alkenes, prior to SNAr reactions
to give 57–59.3. Results and discussion
Compounds were tested for protein kinase inhibition in a panel
of 24 enzymes containing representative members of the major ki-
nome family subclasses, using a commercially available microﬂu-
idic assay format.34,35 Given the small size of most of the
compounds 11–26 (MW range 258–381, median MW = 308), the
inhibitors were tested at a concentration of 30 lM, so that signiﬁ-
cant activity (> 50 % inhibition) would be indicative of ligand
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Figure 2. Heat map showing the % inhibition at 30 lM of 24 kinases by selected compounds from Table 1, Schemes 2–4, grouped by N-substituent (n = 1). Deeper colour
corresponds to greater % inhibition. Data for the control compound H-89 is compiled frommultiple assay determinations. The identity of the residue corresponding to Glu127
in PKA, is shown, determined by sequence alignment and overlay of kinase domain crystal structures.
C. E. Allen et al. / Bioorg. Med. Chem. 21 (2013) 5707–5724 5711efﬁcient binding (> 0.3 kcal1 HA1).36 The ATP concentration used
was approximately the Km,[ATP] for each enzyme tested.37 To deter-
mine the variability and reproducibility of the assay, the pan-AGCkinase inhibitor H-8938 was included as an internal control in each
assay plate. Over multiple assay runs during compound screening,
this control gave high reproducibility with low standard errors in
5712 C. E. Allen et al. / Bioorg. Med. Chem. 21 (2013) 5707–5724the mean % inhibition (Fig. 2). This gave conﬁdence in the robust-
ness of the assay for single-point screening. The determination of %Figure 3. Crystal structures of PKA in complex with (a) 12 (PDB 3ZO1); (b) 14 (PDB
3ZO2); (c) 16 (PDB 3ZO3); (d) 41 (PDB 3ZO4). The ligands are shown with orange
carbon atoms and key amino acid residues from the gatekeeper (M120), hinge
peptide (E121–P124), ribose binding pocket (E127) and DFG-motif (D184–G186)
are shown in light blue. Water molecules are shown as red spheres. Hydrogen
bonding interactions are shown as dashed lines. The electron density shown in
green is from an Fo–Fc omit map contoured at 3r. The ﬁgures were prepared with
CCP4MG.48inhibition at a single ﬁxed concentration, rather than full IC50 or Kd
values for each compound against each kinase, imposes limitations
on the interpretation of the data. The non-linear relationship be-
tween % inhibition and concentration does not permit differentia-
tion between compounds with similar high % inhibitions (e.g.,
between 95–100%), even though there may be signiﬁcantdifferenc-
es in the IC50, and thus selectivity cannot be accurately quantiﬁed.
Nevertheless, the method provides an efﬁcient means to identify
potentially useful activity and distinguish major changes in selec-
tivity patterns that we and others have previously used to assess
kinase inhibition by new screening sets.39–42
The simple heteroaryl-substituted diazaspirocycles 12–18 and
20–26 (Table 1) showed activity proﬁles that were apparently
dominated by the hinge-binder component (Fig. 2). The purines
12–18 were most promiscuous, inhibiting enzymes in the AGC,
TK, CAMK, and CMGC families, with the highest activities against
PKA and other AGC kinases. This was expected since these com-
pounds were closest in structure to the PKA/PKB inhibitors such
as 1,13 and compounds 12–18 generally showed similar activity
patterns to the 4-amino-4-benzylpiperidin-1-yl purine 11. The iso-
quinolines 20–26 showed a reduced spread of activity, inhibiting
only certain AGC and some CAMK kinases. The 4-amino-4-benzyl-
piperidinyl isoquinoline 19 also showed a decrease in the spread of
activity relative to the comparator purine 11. The strong inhibition
of PKA may reﬂect the similarity of the general design 2 to known
isoquinoline-5-sulfonamide PKA inhibitors.24 5-(2,8-Diazaspi-
ro[5.5]undecan-2-ylsulfonyl)isoquinoline (25) showed inhibition
of CHK1 as well as PKA in the screen, and this was conﬁrmed by
IC50 determination43 (25; CHK1 IC50 = 12.8 lM; PKA IC50 = 3.6 lM).
We had speculated that the protonated amine in the diazaspiro-
cycles might provide a binding interaction to the kinase ribose
pocket even with suboptimal hinge binding elements. However,
our screening data indicates that the presence of an appropriate
and correctly oriented hinge binder is critical if the binding contri-
bution of the amine is to be realised, and that the presence of the
protonated amine does not automatically confer promiscuous
inhibition. This is consistent with a Free-Wilson analysis of the
binding contributions of the functional groups in an ATP-competi-
tive 2-(4-(1H-pyrazol-4-yl)phenyl)ethanamine PKA/PKB inhibitor
that adopted a similar binding pose to 1.44
The diazaspirocyclic substituent did modulate the activity of
compounds within the hinge-binder sets. For the purine analogs,
piperidin-4-yl derived scaffolds with a nitrogen atom proximal to
the spirocentre were less promiscuous than those with the more
distal nitrogen (compare 12, 13 to 14, 15). The purines bearing
piperidin-3-yl substituted scaffolds (16, 17) were less active still.
For the isoquinoline analogues the reverse was observed, whereby
the 4-piperidinyl scaffolds with proximal nitrogens (20, 21) were
active at more enzymes in the screen than the compounds with
the nitrogen displaced one atom further around the second ring
(22, 23). Derivatives of the [4.5]-azaspirocycle 5 (e.g., 18, 26),
which had the most extreme difference in positioning of the basic
nitrogen compared to the comparator 4-amino-4-benzylpiperi-
dines 11 and 19, showed very limited activity.
As the purines 12 and 14 showed high activity in the initial
screen, IC50 determinations were carried out against the 24 kinases
using the microﬂuidic assay format and were found to be consis-
tent with values estimated from the single-point percentage inhi-
bition data using the Hill equation, validating the use of the
single concentration screen to assess the library (Supplementary
Material, Table S1). Compound 14 was more potent across the pa-
nel than 12. Both compounds exhibited highest activity against
PKA (IC50 = 80 nM 14, 1 lM 12), with high ligand efﬁciencies
(LE = 0.48 14, 0.41 12). The IC50 values for 14 in the small panel
spanned morethan 3 orders of magnitude (0.08–183 lM), conﬁrm-
ing meaningful selectivity between the most and least inhibited
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low MW compounds is weak, it is efﬁcient and comparable to hits
of similar size that have been successfully progressed to potent
inhibitors.13,14,44 Thus the screening set 12–26 based on two points
of the simple pharmacophore 2 generated novel hits with poten-
tially useful differences in their activity proﬁles.
High resolution crystal structures were obtained of PKA in com-
plex with the purines 12, 14 and 16. The use of PKA as a surrogate
of other AGC family kinases is well established.24,45 The binding
mode for 12 (PDB 3Z01; Fig. 3A) showed the purine hydrogen
bonding to the hinge peptide as expected, and the nitrogen of
the azaspirocycle interacting with the side chain carboxylate of
Glu127, a residue located in the ribose pocket and postulated to
be involved in communicating ATP-binding to substrate–peptide
binding residues.46 Compounds 14 and 16 (PDB 3Z02, 3ZO3;
Fig. 3B, C) bound similarly to the hinge region but displayed an
alternative interaction in the ribose pocket, with the azaspirocycle
nitrogen interacting with the side chain carboxylate of Asp184
from the DFG motif, and close to Asn171 and the backbone car-
bonyl of Glu170. As the DFG aspartate residue is highly conserved
across the kinome due to its role in the enzyme catalytic function,
the different interactions of the nitrogen atoms are consistent with
the increased promiscuity of 14 in the panel compared to 12.
The inhibitory activities of the purines 12 and 13 across the
small panel correlated to an extent with the identity of the residue
equivalent to Glu127 in PKA (Fig. 2). This was determined by se-
quence alignment and overlay of publically available crystal struc-
tures of the kinase domains. For most of the 24 kinases the relevant
residue corresponded to the gatekeeper + 7 position in the kinase
domain sequence, which occupies a position at the start of the ﬁrst
a-helix in the C-terminal subdomain. However for the four mem-
bers of the CMGC family tested and the tyrosine kinase CK1d, there
are differences in the conformation of the peptide loop between
the gatekeeper residue and the start of the a-helix, such that the
gatekeeper + 6 residues occupy this space. Activity was generally
higher for kinases with glutamate at this position (12 and 13, >
50 % inhibition for 6/8 kinases with Glu at this position), with less
likelihood of inhibition when the glutamate was replaced by aspar-
tate or non-acidic residues (12, < 50 % inhibition for 12/16; 13 < 50
% inhibition for 11/16 kinases with non-glutamate residues at this
position). Targeting the presence of the glutamate residue at the
gatekeeper + 7 position is thus potentially useful to direct the
activity proﬁles of the purine-diazaspirocyclic inhibitors towards
a sub-set of kinases. These results conﬁrm that appropriately posi-
tioned basic amines within the core pharmacophore can contribute
positively to potency and selectivity. No similar correlation of
activity was seen for the isoquinoline-diazaspirocyclic compounds,
which is consistent with the different vector expected for the spi-
rocycle relative to the hinge when attached to this topologically
distinct hinge-binder.24
For all three purine compounds 12, 14 and 16 reﬁnement of the
ligand electron density indicated the [5.5]-spirocyclic scaffolds to
adopt chair-chair conformations on binding to PKA. Predicted con-
formations of purines 13, 15, 17 and 18 bound to PKA were gener-
ated through structural modiﬁcation of the most closely related
ligand structure bound to PKA, followed by energy minimization
of the ligand structure within the PKA protein, using the MMFF94X
force ﬁeld in the Molecular Operating Environment (MOE) pro-
gram.47 This modelling suggested that the size of the distal hetero-
cyclic ring (piperidine vs. pyrrolidine), would not signiﬁcantly
affect the binding modes, so that [4.5]-azaspirocycles 13 and 15
closely mimicked the binding of 12 and 14, respectively. The
[4.5]-azaspirocycle 18 was predicted to be unable to simulta-
neously interact with an acidic residue in the main ribose pocket
region and maintain key hinge-binding interactions, consistent
with the poor activity in the screen. The amine of 16 was shownto bind to the DFG aspartate and this compound showed a more
promiscuous proﬁle than 17 which was predicted to contact the
non-conserved glutamate residue.
To conﬁrm the importance of the basic piperidine nitrogen, the
N-Cbz-protected precursors of 14 and 22were proﬁled and showed
reduced activity compared to the corresponding unprotected
piperidines (data not shown). This is potentially due to unfavorable
steric clashes of the bulky substituent in the relatively tight ATP
binding site of many kinases, as well as the removal of interactions
to the protonated amines. Interestingly, in this screening panel
Aurora A kinase was best able to tolerate the N-substitution. In
the purine series, the 3-azaspiro[5.5]undecane 27, and 1-oxa-
and 2-oxa-9-azaspiro[5.5]undecanes 28 and 29were also prepared
(Scheme 2 and Fig. 2). Removal of the basic amine (27) reduced
activities in the panel with the exception of Aurora A kinase,
emphasizing the importance of the basic functionality in the bind-
ing of this set of compounds. Replacement of the nitrogen proximal
to the spirocentre with oxygen to give 28 recovered some of the
AGC and CAMK kinase inhibitory activity, with potent inhibition
of FYN and Aurora A, thus heteroaryl-substituted oxazaspirocycles
may be of future interest as scaffolds for targeting the ribose-pock-
et of a different spectrum of kinases.
Based on its inhibitory proﬁle and binding mode in PKA, purine
analogue 12 was chosen to assess the effects of adding P-loop
interacting substituents at position C-3 and C-4 of the 1,9-diazaspi-
ro[5.5]undecane scaffold. It was expected that the activity proﬁle
of 12 could be sensitive to different functionality in these positions
and therefore hydroxyl, phenyl, benzyl, carboxylate and carboxam-
ide groups were targeted. The purines 33, 35, 41, 42, 45, 48, 51–53,
57–59 and two related isoquinoline analogs (34, 36) were tested
for kinase inhibition at 30 lM for consistency with previous data
(Fig. 2), since the increase in size was limited (MW range 288–
385).
The introduction of hydroxyl groups in 33 and 35 maintained
the activities of 12, except there was a reduction in TK inhibition
(Fig. 2). The hydroxymethyl substituted analogue 53 also main-
tained the original AGC kinase activity, with a reduction in activity
across the other kinases in the panel. Therefore, the addition of hy-
droxyl substituents to the purine [5.5]-azaspirocycle 12, led to a
slight increase in speciﬁcity towards the AGC kinases in the small
panel tested. The presence of a glutamate at the gatekeeper + 7 po-
sition continued to be associated with generally higher activity.
The C-3 and C-4 hydroxyl elaborated scaffolds were also attached
to the isoquinoline-5-sulfonamide hinge-binder, to give 34 and
36. Compared to the parent isoquinoline derivative 20, compounds
34 and 36 showed increased inhibition of AGC kinases, in particu-
lar for RSK1, PKA and MSK1. In contrast to the purine analogues,
isoquinolines 20, 49 and 51 showed no inhibition of PKB isoforms
(AKT1 and AKT2), despite the high sequence similarity of these
proteins with PKA.45
Phenyl and benzyl substituents were introduced at the C-4
position of the 1,9-diazaspiro[5.5]undecane, to give 41 and 42.
Compounds 41 and 42 showed increased activity towards the
AGC sub-family compared to 12. This was consistent with the
activity proﬁle of the 4-benzyl-4-aminopiperidin-1-yl purine
inhibitor 11. There was an appreciable increase in TK activity for
the phenyl substituted analogue 41, but this was less marked for
the benzyl substituted compound 42 (Fig. 2). For compounds 11,
41 and 42 the addition of the P-loop targeting aromatic group re-
duced the inﬂuence on the activity pattern of the presence of gluta-
mate at the gatekeeper + 7 residue, so that non-polar residues in this
position became more frequently associated with higher activities.
Elaboration at the C-3 position of 12 to give 45 and 48 resulted
in a reduction in overall activity, but maintained some selectivity
towards the AGC kinases. The C-3 position of 12was also function-
alised to give the methyl ester 51 and the amides 57–59. The ester
Figure 4. Model of 1,9-diazaspiro[5.5]undecanes bound to PKA, generated by
energy minimization of the elaborated structure of 12 within the PKA protein using
the MMF94X force ﬁeld within MOE;47 (A) Comparison of 4-substituted 1,9-
diazaspiro[5.5]undecanes 41 (green) and 42 (magenta); (B) Comparison of 3-
substituted 1,9-diazaspiro[5.5]undecanes 45 (cyan) and 48 (blue). The P-loop and
hinge peptide of PKA are shown as cartoons (grey).
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pared to the parent purine [5.5]-azaspirocycle 12 (Fig. 2) but en-
hanced selectivity for the AGC kinases. The acid 52 also had less
activity against the kinases in the panel, but altered the proﬁle of
the undecorated [5.5]-azaspirocycle 12 towards AurA and RSK1
(AurA IC50 = 6.1 lM).43
The single-concentration inhibitory activities of 41, 42 and 45
were determined against a 96-member kinase panel distributed
across eight of the kinome sub-families, with the majority of ki-
nases representing the four main sub-families (AGC, CAMK, CMGC
and TK) (Supplementary Material, Table S2). This broader analysis
conﬁrmed that the C-4 elaborated phenyl 41 and benzyl 42 purine
[5.5]-azaspirocycles possessed a degree of selectivity towards the
AGC kinases. However, there was still signiﬁcant inhibition of the
kinases in the TK and CAMK sub-families by 41 and in the CAMK
sub-family by 42. A reduction in overall activity was conﬁrmed
for the C-3 benzyl substituted compound 45, particularly in the
AGC kinase sub-family compared to 41 and 42. Although 12, 41,
42 and 45 have a broad range of inhibitory activities, these screen-
ing data show that variation of the positioning of a lipophilic group
interacting with the P-loop can vary the pattern of inhibition.
The substituted inhibitors 41, 42, 45, 48 were modelled in the
ATP-binding site of PKA starting from the bound conformation of
12 in PKA. This suggested that the aryl rings of 41 and 42 could
project along a vector towards the P-loop, however the extra car-
bon of the benzyl group of 42 would enable a closer interaction
(Fig. 4A), consistent with the increased inhibition of AGC and
other kinases within the panels by 42. Modelling of compounds
45 and 48 also showed the substituents approaching the P-loop,
however they would likely require additional substitution to efﬁ-
ciently bind without compromising hinge peptide and ribose
pocket binding interactions (Fig.4B). A crystal structure of 41
bound to PKA was determined (PDB 3ZO4; Fig. 3D) and showed
interesting differences with the binding of 12, and with the pre-
diction of 41 binding. A key variation was in the conformation
of the spirocyclic core scaffold. Whereas the electron density for
12 bound to PKA was consistent with a chair-chair conformation
of the spirocycle, the ﬁrst piperidine ring of 41 adopted a twist-
boat conformation. This led to the projection of the equatorial
phenyl substituent along a more direct vector to the P-loop than
was predicted from the model based on the chair-chair conforma-
tion of 12 (Fig. 4A). The phenylsubstituent of 41 in PKA occupied
a similar space to the terminal 4-chloro substituent of 1 in PKA–
PKB chimeric protein (Fig. 1) and sat within a hydrophobic envi-
ronment created by the P-loop backbone and the side chain of
Val57. The spirocyclic amine 41 formed hydrogen bonds directly
to the side chain of Glu127 and the backbone carbonyl of
Glu170, with a water-mediated contact to the side chain of
Asn171. The distortion of the azaspirocycle conformation from a
chair–chair (12) to twist-boat-chair (41) would suggest that any
additional energy of binding obtained by 41 from contacting the
P-loop could be offset by induced strain in the ligand. This was
supported by the measured IC50 for inhibition of PKA43 by
41(IC50 = 149 nM) which, although substantially increased over
12 (IC50 = 1000 nM), was less improved than that of the C-4 ben-
zylated analogue 42 (IC50 = 31 nM) where binding to the P-loop
was expected to be compatible with maintaining a lower energy
chair-chair conformation of the spirocycle.
In the above analysis, the changes in activity proﬁle could be re-
lated in part to speciﬁc interactions of the ligands in the ATP site.
However, the degree to which the distinct activity proﬁles of frag-
ments or low-to-moderate molecular weight hit compounds such
as those described here can be maintained and exploited during
elaboration to larger molecular weight species is not yet fully
deﬁned.39,40 While the results of this study are encouraging for
the identiﬁcation of starting points with different spectra of kinaseinhibitory activities, to realize the controlled design of ATP-com-
petitive kinase inhibitors with speciﬁc polypharmacology8,9 would
require more information on the inherent stability, or otherwise, of
kinase selectivity proﬁles during optimization of other important
molecular properties.
4. Conclusions
Heteroaryl-substituted diazaspirocyclic compounds were pre-
pared as potential ATP-competitive kinase inhibitors based on
the pharmacophore deﬁned by the 4-aminopiperidin-1-yl purine
PKB inhibitor 1 and ATP, and in particular to exploit the interac-
tions of basic nitrogen atoms in the ribose pocket. Several com-
pounds showing ligand efﬁcient inhibition of multiple kinases
were identiﬁed, validating the design. The nature of the adenine-
mimic largely determined the inhibitory activities shown by
simpler spirocyclic compounds, with structural similarity to 1
conferring a similar activity proﬁle, particularly inhibition of AGC
kinases. However, varying the hinge-binding and diazaspirocyclic
groups to produce compounds more structurally distinct to 1 also
produced potentially useful variation in the inhibition proﬁles.
Altering the position of the basic nitrogen in the diazaspirocycles
was expected to change the interactions to the proteins. This was
conﬁrmed by X-ray crystallography in the case of purine-substi-
tuted examples, and was associated with changes in the activity
proﬁles. Interaction of the basic amine with a non-conserved
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pocket conferred activity to purines substituted with diazaspirocy-
cles containing an embedded 4-aminopiperidine motif.
Ring-closing metathesis was used to enable versatile syntheses
of 1,9-diazaspiro[5.5]undecanes substituted at two positions with
polar and hydrophobic groups to target the P-loop of the kinase ac-
tive site within a series of purine derivatives. These routes should
be readily extendable to prepare other substituted diazaspirocy-
cles. The introduction of aryl substituents at C-4 of the N-purinyl
1,9-diazaspiro[5.5]undecane scaffold led to the greatest increases
in activity, which was consistent with modeling that proposed this
substitution pattern would most closely resemble the original PKB
inhibitor 1. Importantly, substitution at C-3 with corresponding
aryl groups led to different activity proﬁles, suggesting that the
addition of the P-loop targeting elements could change the intrin-
sic activity proﬁle of the purine-diazaspirocyclic scaffolds. The C-4
phenyl substituted analogue 41 in PKA showed a change in the
conformation of the core spirocycle from chair-chair to twist
boat-chair to enable binding of the P-loop targeting group, show-
ing that a range of conformations are accessible to the diazaspiro-
cyclic parts of the scaffolds.
Overall these results show that diazaspirocyclic motifs can be
usefully incorporated into the core binding scaffolds of kinase
inhibitors and that these motifs adopt well-deﬁned conformations
within the ATP-site leading to productive interactions. Different ki-
nase inhibitory proﬁles can be associated with speciﬁc changes to
the substitution pattern of the spirocycle and its orientation with
respect to the hinge-binding heteroaryl group. The straightforward
synthetic routes we have demonstrated to make novel substituted
diazaspirocycles increase the potential application of these scaf-
folds for future inhibitor discovery.5. Experimental
5.1. General synthetic chemistry
Reactions were carried out under N2. Organic solutions were
dried over MgSO4 or Na2SO4. Starting materials and solvents were
purchased from commercial suppliers and were used without fur-
ther puriﬁcation. Microwave reactions were carried out using a
Biotage Initiator microwave reactor. Flash column chromatography
was performed using Merck silica gel 60 (0.040–0.063 mm). Gradi-
ent silica column chromatography was performed with a Biotage
SP1 medium pressure chromatography system, using prepacked
silica gel cartridges. Preparative HPLC was performed using a Gil-
son GX-281 Liquid Handler system and Gilson 322 HPLC pump,
with a 15 minute gradient elution of 10–90% MeOH/0.1% aqueous
formic acid at a ﬂow rate of 20 mL min1. Ion exchange chromatog-
raphy was performed using Isolute Flash SCX-II acidic resin car-
tridges. Melting points were determined on a Leica Gallen III or a
SRS EZ-Melt Automated melting point apparatus. 1H NMR spectra
were recorded on a Bruker AMX500 instrument at 500 MHz using
internal deuterium locks. Chemical shifts (d) are reported relative
to TMS (d = 0) and referenced to the solvent in which they were
measured. 13C-nuclear magnetic resonance spectra were recorded
at 126 MHz on a Bruker AMX500 spectrometer using an internal
deuterium lock. Combined HPLC–MS analyses were performed on
a Waters Alliance 2795 separations module and a Waters 2487
dual wavelength absorbance detector coupled to a Waters/Micro-
mass LCt time of ﬂight mass spectrometer with ESI source, or on
an Agilent 1200 series HPLC and diode array detector coupled to
a 6210 time of ﬂight mass spectrometer with dual multimode
APCI/ESI source. HPLC was performed using Supelco DISCOVERY
C18, 50 mm  4.6 mm or 30 mm  4.6 mm i.d. columns, or using
an Agilent 6210 TOF HPLC–MS with a Phenomenex Gemini 3 lmC18 (3 cm  4.6 mm i.d.) column. Both HPLC systems were run at
a temperature of 22 C with gradient elution of 10–90% MeOH/
0.1% aqueous formic acid at a ﬂow rate of 1 mL min1. UV detection
was at 254 nm and ionisation was by positive or negative ion elec-
trospray as indicated. The molecular weight scan range was 50–
1000 amu. All tested compounds gave >95% purity as determined
by these methods. All puriﬁed synthetic intermediates gave >95%
purity as determined by these methods except where indicated
in the text.
5.1.1. Benzyl 1,8-diazaspiro[4.5]decane-1-carboxylate (9)
A solution of Et3N (1.1 mL, 0.80 mmol), 517 (50 mg, 0.20 mmol)
and CbzCl (37 lL, 0.26 mmol) in CH2Cl2 (2 mL) was stirred at rt for
48 h. Additional CbzCl (15 lL, 0.10 mmol) and Et3N (0.2 mL,
0.20 mmol) were added and the mixture was stirred for a further
24 h. The mixture was washed with satd aq NaHCO3 (3  5 mL),
dried and concentrated. Flash column chromatography, eluting
with 30% EtOAc/hexane, gave 1-benzyl 8-tert-butyl 1,8-diazaspi-
ro[4.5]decane-1,8-dicarboxylate as colourless oil (61 mg,
0.15 mmol, 82%). 1H NMR (500 MHz, CDCl3) d 1.23–1.36 (2H, m),
1.46 (9H, s), 1.76–1.83 (2H, m), 1.90–1.99 (2H, m), 2.66–2.81
(4H, m), 3.49–3.58 (2H, m), 4.02–4.22 (2H, m), 5.09 (2H, s), 7.20–
7.37 (5H, m); 13C NMR (126 MHz, CDCl3) d 22.1, 28.5, 33.0, 35.0,
41.3, 42.3, 47.7, 62.8, 66.1, 79.4, 127.7, 127.8, 128.4, 137.2, 153.6,
154.6; LC–MS (ESI+) m/z 397 (M + Na); tR = 2.77 min, purity = 90%;
HRMS m/z calcd for C21H30N2O4Na (M+Na) 397.2098, found
397.2104. A solution of 4 M HCl in dioxane (2.37 mL, 9.50 mmol)
and 1-benzyl 8-tert-butyl 1,8-diazaspiro[4.5]decane-1,8-dicarbox-
ylate (358 mg, 0.95 mmol) in MeOH (5 mL) was stirred at 0 C for
1 h, then at 4 C for 16 h. The reaction mixture was concentrated
and puriﬁed by ion exchange chromatography on acidic resin, elut-
ing with 2 M NH3 in MeOH, to give 9 as a colourless oil (261 mg,
0.95 mmol, 100%); 1H NMR (500 MHz, CDCl3) d 1.31–1.38 (2H,
m), 1.75–1.81 (2H, m), 1.92–2.01 (2H, m), 2.60–2.69 (4H, m),
3.02–3.13 (2H, m), 3.49–3.57 (2H, m), 5.04–5.25 (2H, m), 7.29–
7.45 (5H, m); 13C NMR (126 MHz, CDCl3) d 22.3, 34.7, 35.8, 44.7,
47.6, 62.9, 66.0, 127.7, 127.7, 128.4, 137.3, 153.6; LC–MS (ESI+)
m/z 275 (M+H); HRMS m/z calcd for C16H23N2O2 (M+H)
275.1754, found 275.1752.
5.1.2. Benzyl 2,9-diazaspiro[5.5]undecane-2-carboxylate (10)
A solution of Et3N (0.1 mL, 0.68 mmol), 6 (50 mg, 0.17 mmol)
and CbzCl (38 mg, 0.22 mmol) in CH2Cl2 (1.7 mL) was stirred at
rt for 48 h. Additional CbzCl (29 mg, 0.16 mmol) was added and
the mixture was stirred for a further 24 h. The mixture was washed
with satd aq NaHCO3 (3  10 mL), dried and concentrated to give
2-benzyl 9-tert-butyl 2,9-diazaspiro[5.5]undecane-2,9-dicarboxyl-
ate as a colourless oil (55 mg, 0.13 mmol, 65%). 1H NMR
(500 MHz, CDCl3) d 1.30–1.38 (2H, m), 1.38–1.50 (13H, m), 1.54–
1.62 (2H, m), 3.16–3.61 (8H, m), 5.15 (2H, s), 7.30–7.41 (5H, m);
13C NMR (126 MHz, CDCl3) d 20.8, 21.0, 28.5, 32.1, 33.4, 35.5,
35.8, 39.5, 44.9, 51.4, 51.8, 67.1, 79.3, 127.0, 127.6, 127.9, 128.1,
128.5, 128.6, 136.9, 154.9, 155.4, 155.5, multiple peaks due to rota-
mers; LC–MS (ESI+) m/z 411 (M+Na); tR = 2.85 min, purity = 90%;
HRMS m/z calcd for C22H32N2O4Na (M+Na) 411.2254, found
411.2252. A solution of 4 M HCl in dioxane (0.35 mL, 1.41 mmol)
and 2-benzyl 9-tert-butyl 2,9-diazaspiro[5.5]undecane-2,9-dicar-
boxylate (55 mg, 0.14 mmol) in MeOH (3 mL) was mixed at 0 C
then stirred at 4 C for 16 h. The mixture was concentrated and
puriﬁed by ion exchange chromatography on acidic resin, eluting
with 2 M NH3 in MeOH, to give 10 as a colourless oil (32 mg,
0.11 mmol, 80%). 1H NMR (500 MHz, CDCl3) d 1.29–1.50 (6H, m),
1.51–1.59 (2H, m), 2.25 (1H, s), 2.68–2.89 (4H, m), 3.29–3.32
(1H, s), 3.32–3.36 (1H, s), 3.41–3.45 (2H, m), 5.12 (2H, s), 7.29–
7.37 (5H, m); 13C NMR (126 MHz, CDCl3) d 20.6, 21.0, 32.2, 34.7,
36.2, 36.5, 42.0, 44.9, 51.8, 52.4, 67.0, 127.8, 128.0, 128.5, 136.9,
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(M+H); HRMS m/z calcd for C17H25N2O2 (M+H) 289.1911, found
289.1921.
5.1.3. 4-Benzyl-1-(9H-purin-6-yl)piperidin-4-amine (11)
A solution of Et3N (0.3 mL, 2.30 mmol) 323 (89 mg, 0.46 mmol)
and 6-chloropurine (72 mg, 0.46 mmol) in nBuOH (4.6 mL) was
heated at 100 C for 18 h. The reaction mixture was cooled and
concentrated to dryness. The solid was washed with MeOH to give
11 as an off-white solid (101 mg, 0.35 mmol, 72%). mp 232 C
(dec); 1H NMR (500 MHz, DMSO-d6) d 1.31–1.38 (2H, m), 1.53
(2H, ddd, J = 13.5, 12.5, 4.0 Hz), 2.64 (2H, s), 3.14–3.36 (2H, br
m), 3.55–3.72 (2H, br m), 4.76–5.09 (2H, br m), 7.17–7.22 (3H,
m), 7.25–7.29 (2H, m), 8.06 (1H, s), 8.16 (1H, s); 13C NMR
(126 MHz, DMSO-d6) d 37.0, 40.8, 49.8, 50.0, 118.6, 126.0, 127.7,
130.6, 137.4, 137.6, 151.3, 151.8, 153.0; LC–MS (ESI+) m/z 292
(M-NH2); HRMS m/z calcd for C17H21N6 (M+H) 309.1822, found
309.1825.
5.1.4. 6-(1,9-Diazaspiro[5.5]undecan-9-yl)-9H-purine (12)
A solution of Et3N (0.24 mL, 1.70 mmol), 417 (100 mg,
0.34 mmol) and 6-chloropurine (55 mg, 0.34 mmol) in nBuOH
(3.4 mL) was stirred at 100 C for 24 h. The reaction mixture was
cooled, concentrated and triturated with MeOH (2.5 mL). The
resulting solid was collected and dried to give tert-butyl 9-(9H-
purin-6-yl)-1,9-diazaspiro[5.5]undecane-1-carboxylate as a yellow
solid (107 mg, 0.29 mmol, 84%). A mixture of 4 M HCl in dioxane
(0.35 mL, 2.80 mmol) and tert-butyl 9-(9H-purin-6-yl)-1,9-diaza-
spiro[5.5]undecane-1-carboxylate (107 mg, 0.28 mmol) in MeOH
(2 mL) was stirred at rt for 48 h. The mixture was concentrated
and puriﬁed by ion exchange chromatography on acidic resin, elut-
ing with 2 M NH3 in MeOH to give 12 as an off-white solid (66 mg,
0.24 mmol, 84%). mp 250–256 C; 1H NMR (500 MHz, DMSO-d6) d
1.34–1.48 (6H, m), 1.51–1.57 (2H, m), 1.64–1.77 (2H, m), 2.69–
2.71 (2H, m), 3.79–3.91 (2H, br m), 4.49–4.70 (2H, brd m), 8.07
(1H, s), 8.15 (1H, s); 13C NMR (126 MHz, DMSO-d6) d 19.9, 26.9,
35.1, 36.7, 40.3, 40.7, 48.8, 118.7, 137.7, 151.4, 151.8, 153.1; LC–
MS (ESI+) m/z 273 (M+H); HRMS m/z calcd for C14H21N6 (M+H)
273.1822, found 273.1822.
5.1.5. 6-(1,8-Diazaspiro[4.5]decan-8-yl)-9H-purine (13)
A mixture of Et3N (0.21 mL, 1.55 mmol), 9 (87 mg, 0.31 mmol)
and 6-chloropurine (49 mg, 0.31 mmol) in nBuOH (1 mL) was
heated to 100 C for 16 h. The mixture was cooled to room temper-
ature and concentrated to dryness. The solid was washed with
MeOH (2 mL) to give benzyl 8-(9H-purin-6-yl)-1,8-diazaspi-
ro[4.5]decane-1-carboxylate as an off-white solid (84 mg,
0.21 mmol, 69%). A mixture of 6 M HCl (1 mL) and benzyl 8-(9H-
purin-6-yl)-1,8-diazaspiro[4.5]decane-1-carboxylate (40 mg,
0.10 mmol) was heated in a microwave reactor to 100 C for
15 min. The mixture was concentrated and puriﬁed by column
chromatography, eluting with 10% 2 M NH3 in MeOH/CH2Cl2 to
give 13 as an off-white solid (26 mg, 0.10 mmol, 99%). mp 223–
235 C; 1H NMR (500 MHz, d6-DMSO) d 1.56–1.63 (6H, m), 1.76
(2H, dddd, J = 7.0, 7.0 Hz), 2.93 (2H, dd, J = 7.0, 7.0 Hz), 4.10–4.29
(4H, br m), 8.09 (1H, s), 8.19 (1H, s); 13C NMR (126 MHz, d6-DMSO)
d 24.9, 36.7, 36.8, 42.8, 45.1, 61.2, 119.2, 138.4, 151.9, 152.3, 153.5;
LC–MS (ESI+) m/z 259 (M+H); HRMS m/z calcd for C13H19N6 (M+H)
259.1666, found 259.1658.
5.1.6. 6-(2,9-Diazaspiro[5.5]undecan-9-yl)-9H-purine (14)
A mixture of Et3N (0.19 mL, 1.35 mmol), 10 (78 mg, 0.27 mmol)
and 6-chloropurine (42 mg, 0.27 mmol) in nBuOH (2.7 mL) was
heated to 100 C for 16 h. The mixture was cooled and concen-
trated to dryness. Flash column chromatography eluting with 5%
MeOH/CH2Cl2 gave benzyl 9-(9H-purin-6-yl)-2,9-diazaspi-ro[5.5]undecane-2-carboxylate as a white solid (67 mg, 0.17 mmol,
61%). A mixture of CF3CO2H (4 mL) and benzyl 9-(9H-purin-6-yl)-
2,9-diazaspiro[5.5]undecane-2-carboxylate (53 mg, 0.13 mmol)
was heated to 50 C for 24 h. The mixture was concentrated and
puriﬁed by ion exchange chromatography, eluting with 2 M NH3
in MeOH, to give 14 as a pale yellow oil (35 mg, 0.13 mmol,
100%). mp = 246–247 C; 1H NMR (500 MHz, CDCl3) d 1.54–1.58
(4H, m), 1.62–1.67 (4H, m), 2.73 (2H, s), 2.80–2.83 (2H, m), 4.15–
4.43 (2H, br m), 5.02–5.69 (2H, br m), 7.93 (1H, s), 8.35 (1H, s);
13C NMR (126 MHz, CDCl3) d 22.2, 31.2, 34.7, 34.7, 41.0, 47.2,
55.8, 119.6, 136.7, 151.2, 151.5, 153.9; LC–MS (ESI+) m/z 273.14
(M+H); HRMS m/z calcd for C14H21N6 (M+H) 273.1822, found
273.1828.
5.1.7. 6-(2,8-Diazaspiro[4.5]decan-8-yl)-9H-purine (15)
Prepared as described for 12 starting from 8 and 6-chloropurine
to give 15 as a colourless oil (53% over 2 steps); 1H NMR (500 MHz,
CDCl3) d 1.47–1.63 (6H, m), 2.66 (2H, s), 2.87 (2H, dd, J = 7.5,
7.5 Hz), 4.00–4.43 (4H, br m), 8.09 (1H, s), 8.19 (1H, s); 13C NMR
(126 MHz, CDCl3) d 36.1, 37.7, 42.0, 43.2, 45.6, 57.7, 119.2, 138.4,
151.9, 152.2, 153.6; LC–MS (ESI+) m/z 259 (M+H); HRMS m/z calcd
for C13H19N6 (M+H) 259.1666, found 259.1669.
5.1.8. 6-(2,9-Diazaspiro[5.5]undecan-2-yl)-9H-purine (16)
Prepared as described for 12 starting from 6 and 6-chloropurine
to give 16 as a white solid (60% over 2 steps). mp 183–187 C; 1H
NMR (500 MHz, CDCl3) d 1.49 (2H, ddd, J = 13.5, 9.5, 4.0 Hz, C7/
10-Hax), 1.61–1.68 (4H, m, C7/10-H, C4-H), 1.74–1.80 (2H, m,
C3-H), 2.90–2.96 (2H, m, C8/9-H), 3.06–3.13 (2H, m, C8/9-H),
4.14–4.44 (4H, brd m, C2/6-H), 7.95 (1H, s, C14-H), 8.34 (1H, m,
C12-H); 13C NMR (126 MHz, CDCl3) d 21.2 (C3), 33.2 (C5), 33.9
(C7/10), 36.8 (C4), 41.4 (C8/9), 119.1 (CAr), 136.6 (C14), 151.2
(CAr), 151.7 (C12), 154.24 (CAr), (C2 and C6 Missing); HRMS
[M+H+] calcd for C14H21N6 274.1848; found 274.1849.
5.1.9. 6-(2,8-Diazaspiro[5.5]undecan-2-yl)-9H-purine (17)
Prepared as described for 12 starting from 7 and 6-chloropurine
to give 17 as a yellow oil (48% over 2 steps). 1H NMR (500 MHz,
CDCl3) d 1.40–1.76 (8H, m), 2.46 (1H, d, J = 13.0 Hz), 2.67 (1H, dd,
J = 11.5, 11.5 Hz), 2.98–3.10 (1H, br s), 3.11–3.14 (1H, m), 3.41
(1H, d, J = 13.0 Hz), 4.77–5.10 (2H, br m), 5.65–6.07 (2H, m), 7.88
(1H, s), 8.33 (1H, s); 13C NMR (126 MHz, CDCl3) d 21.1, 21.8, 33.5,
34.2, 35.7, 45.0 (br), 46.1, 51.6, 117.0, 137.3, 151.4, 152.2, 153.4;
LC–MS (ESI+) m/z 273 (M+H); HRMS m/z calcd for C14H21N6
(M+H) 273.1822, found 273.1835.
5.1.10. 6-(1,8-Diazaspiro[4.5]decan-1-yl)-9H-purine (18)
Prepared as described for 12 starting from 5 and 6-chloropurine
to give 18 as a colourless oil (7% over 2 steps). 1H NMR (500 MHz,
DMSO-d6) d 1.45–1.52 (2H, m), 1.88–1.96 (2H, m), 2.06–2.12 (2H,
m), 2.87–2.99 (2H, m), 3.19–3.25 (2H, m), 3.44–3.56 (2H, m),
4.22–4.27 (2H, m), 8.07 (1H, s), 8.19 (1H, s); 13C NMR (126 MHz,
DMSO-d6) d 22.5, 29.7, 30.5, 36.1, 40.0, 51.2; 150.9, 4 quaternary
carbons not observed. LC–MS (ESI+) m/z 260 (M+H); HRMS m/z
calcd for C13H19N6 259.1666, found 259.1663.
5.1.11. 4-Benzyl-1-(isoquinolin-5-ylsulfonyl)piperidin-4-amine
(19)
A solution of Et3N (0.3 mL, 2.19 mmol), 323 (100 mg, 0.53 mmol)
and 5-isoquinoline sulfonylchloride (120 mg, 0.44 mmol) in CH2Cl2
(5 mL) was stirred at rt for 16 h. The mixture was diluted with H2O
(5 mL) and washed with H2O (3  10 mL). The organic layer was
dried and concentrated. Flash column chromatography eluting
with 1–5% MeOH/CH2Cl2 gave 19 as a pale yellow oil (65 mg,
0.17 mmol, 33%). 1H NMR (500 MHz, CDCl3) d 1.35–1.41 (2H, m),
1.73 (2H, ddd, J = 12.0, 12.0, 4.0 Hz), 2.61 (2H, s), 2.99 (2H, ddd,
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(2H, m), 7.31–7.22 (3H, m), 7.71 (1H, dd, J = 7.5, 7.5 Hz), 8.21 (1H,
dd, J = 7.5, 1.0 Hz), 8.38 (1H, dd, J = 7.5, 1.0 Hz), 8.52 (1H, d,
J = 6.0 Hz), 8.67 (1H, d, J = 6.0 Hz), 9.35 (1H, s); 13C NMR
(126 MHz, CDCl3) d 37.0, 41.8, 49.3, 51.5, 117.8, 125.9, 126.7,
128.2, 129.1, 130.5, 132.0, 133.0, 133.6, 133.9, 136.2, 145.0,
153.2; LC–MS (ESI+)m/z 382 (M+H); HRMSm/z calcd for C21H24N3-
O2S (M+H) 382.1584, found 382.1601.
5.1.12. 5-(1,9-Diazaspiro[5.5]undecan-9-ylsulfonyl)isoquinoline
(20)
A mixture of Et3N (0.12 mL, 0.85 mmol), 417 (50 mg, 0.17 mmol)
and 5-isoquinoline sulfonyl chloride (89 mg, 0.34 mmol) in CH2Cl2
(1.7 mL) was stirred at rt for 16 h. The reaction was quenched with
H2O (5 mL) and washed with H2O (3  5 mL). The organic layer
was dried and concentrated. Flash column chromatography eluting
with 0–5% MeOH/CH2Cl2 (0.1% Et3N) gave tert-butyl 9-(isoquino-
lin-5-ylsulfonyl)-1,9-diazaspiro[5.5]undecane-1-carboxylate as a
light brown oil (50 mg, 0.11 mmol, 66%). A mixture of 4 M HCl in
dioxane (0.26 mL, 1.05 mmol) and tert-butyl 9-(isoquinolin-5-yls-
ulfonyl)-1,9-diazaspiro[5.5]undecane-1-carboxylate (47 mg,
0.11 mmol) in MeOH (1 mL) was stirred at rt for 16 h. The mixture
was concentrated and puriﬁed by ion exchange chromatography
on acidic resin eluting with 2 M NH3 in MeOH to give 20 as a dark
orange oil (33 mg, 0.10 mmol, 91%). 1H NMR (500 MHz, CDCl3) d
1.34–1.38 (2H, m), 1.40–1.47 (2H, m), 1.52–1.58 (2H, m), 1.62
(2H, ddd, J = 10.0, 12.0, 4.0 Hz), 1.67–1.74 (2H, m), 2.69 (2H, t,
J = 7.0 Hz), 3.11–3.20 (2H, m), 3.35–3.43 (2H, m), 7.72 (1H, dd,
J = 7.5, 7.5 Hz), 8.22 (1H, d, J = 7.5 Hz), 8.40 (1H, d, J = 7.5 Hz),
8.54 (1H, d, J = 6.0 Hz), 8.70 (1H, d, J = 6.0 Hz), 9.36 (1H, s); 13C
NMR (126 MHz, CDCl3) d 19.8, 26.6, 35.0, 36.8, 40.3, 41.4, 48.0,
117.7, 125.9, 129.1, 132.0, 126.9, 133.1, 133.8, 145.1, 153.3; LC–
MS (ESI+) m/z 346 (M+H); HRMS m/z calcd for C18H24N3O2S
(M+H) 346.1584, found 346.1587.
5.1.13. 5-(1,8-Diazaspiro[4.5]decan-8-ylsulfonyl)isoquinoline
(21)
4 M HCl in dioxane (1.77 mL, 7.10 mmol) was added to a solu-
tion of 517 (171 mg, 0.71 mmol) in MeOH (4 mL) and stirred at rt
for 16 h. The reaction mixture was concentrated to give crude
1,8-diazaspiro[4.5]decane dihydrochloride salt (150 mg). Et3N
(0.79 mL, 5.68 mmol) and 5-isoquinoline sulfonyl chloride
(188 mg, 0.71 mmol) were added to the crude 1,8-diazaspi-
ro[4.5]decane dihydrochloride salt in CH2Cl2 (6 mL) and the mix-
ture was stirred at rt for 16 h. The reaction was quenched with
H2O (5 mL) and washed with H2O (3  5 mL). The organic layer
was dried and concentrated. Flash column chromatography eluting
with 5% MeOH/CH2Cl2 gave 21 as an orange oil (41 mg, 0.12 mmol,
17% over 2 steps). 1H NMR (500 MHz, CDCl3) d 1.71 (2H, dd, J = 7.5,
7.5 Hz), 1.81 (2H, ddd, J = 13.0, 9.0, 3.0 Hz), 1.88–1.96 (4H, m), 3.10
(2H, dd, J = 7.0, 7.0 Hz), 3.25–3.32 (2H, m), 3.38–3.46 (2H, m), 7.71
(1H, dd, J = 7.5, 7.5 Hz), 8.22 (1H, d, J = 7.5 Hz), 8.38 (1H, d,
J = 7.5 Hz), 8.45 (1H, d, J = 6.0 Hz), 8.68 (1H, d, J = 6.0 Hz), 9.34
(1H, s); 13C NMR (126 MHz, CDCl3) d 23.3, 34.6, 36.1, 42.8, 44.6,
62.9, 117.6, 126.0, 129.2, 131.9, 132.7, 133.9, 134.0, 145.2, 153.3;
LC–MS (ESI+) m/z 332 (M+H); HRMS m/z calcd for C17H22N3O2S
(M+H) 332.1427, found 332.1432.
5.1.14. 5-(2,9-Diazaspiro[5.5]undecan-9-ylsulfonyl)isoquinoline
(22)
A solution of Et3N (0.16 mL, 1.20 mmol), 10 (70 mg, 0.24 mmol)
and 5-isoquinoline sulfonyl chloride (126 mg, 0.48 mmol) in CH2-
Cl2 (2 mL) was stirred at rt for 16 h then quenched with H2O
(5 mL). The organic layer was washed with H2O (3  5 mL), dried
and concentrated. Flash column chromatography eluting with
50% EtOAc/hexane gave benzyl 9-(isoquinolin-5-ylsulfonyl)-2,9-diazaspiro[5.5]undecane-2-carboxylate as a clear oil (68 mg,
0.14 mmol, 59%). A mixture of CF3CO2H (4 mL) and benzyl 9-(iso-
quinolin-5-ylsulfonyl)-2,9-diazaspiro[5.5]undecane-2-carboxylate
(58 mg, 0.13 mmol) was heated to 45 C for 16 h. The mixture was
cooled and concentrated. Column chromatography on a Biotage
KP-NH column, eluting with 1% EtOH/CH2Cl2, gave 22 as a light yel-
low oil (10 mg, 0.03 mmol, 23%). 1H NMR (500 MHz, CDCl3) d 1.40–
1.71 (6H, m), 1.74–1.79 (2H, m), 2.80 (2H, s), 2.95–3.06 (4H, m),
3.19–3.23 (2H, m), 7.74 (1H, dd, J = 8.0, 7.5 Hz), 8.20–8.25 (1H,
m), 8.39–8.43 (1H, m), 8.45 (1H, d, J = 6.0 Hz), 8.69 (1H, d,
J = 6.0 Hz), 9.38 (1H, s); 13C NMR (126 MHz, CDCl3) d 18.1, 30.4,
31.9, 33.4, 40.8, 44.1, 51.0, 117.5, 125.9, 129.1, 131.8, 132.5,
134.0, 134.3, 145.1, 153.3; LC–MS (ESI+) m/z 346 (M+H); HRMS
m/z calcd for C18H24N3O2S (M+H) 346.1584, found 346.1593.
5.1.15. 5-(2,8-Diazaspiro[4.5]decan-8-ylsulfonyl)isoquinoline
(23)
Prepared as described for 20 starting from 8 and 5-isoquinoline
sulfonyl chloride to give 23 as a colourless oil (29% over 2 steps). 1H
NMR (500 MHz, CDCl3) d 1.54 (2H, dd, J = 7.0, 7.0 Hz), 1.61–1.64
(4H, m), 2.12 (1H, br s), 2.69 (2H, s), 2.99 (2H, dd, J = 7.0, 7.0 Hz),
3.15–3.21 (2H, m), 3.22–3.28 (2H, m), 7.74 (1H, dd, J = 7.5,
7.5 Hz), 8.23–8.26 (1H, m), 8.41 (1H, dd, J = 7.5, 1.5 Hz), 8.49–
8.52 (1H, m), 8.71 (1H, d, J = 6.5 Hz), 9.38 (1H, d, J = 1.0 Hz); 13C
NMR (126 MHz, CDCl3) d 35.5, 37.0, 40.9, 43.5, 45.7, 57.4, 117.7,
125.8, 129.1, 131.9, 132.8, 133.8, 134.1, 145.1, 153.3; LC–MS
(ESI+) m/z 332 (M+H); HRMS m/z calcd for C17H22N3O2S (M+H)
332.1427, found 332.1437.
5.1.16. 5-(2,9-Diazaspiro[5.5]undecan-2-ylsulfonyl)isoquinoline
(24)
Prepared as described for 20 starting from 6 and 5-isoquinoline
sulfonyl chloride to give 24 as a colourless oil (52% over 2 steps). 1H
NMR (500 MHz, CDCl3) d 1.26–1.40 (6H, m), 1.60–1.66 (2H, m),
2.57–2.63 (2H, ddd, J = 12.5, 8.5, 3.5 Hz), 2.65–2.71 (2H, m), 2.96
(2H, s), 3.14–3.18 (2H, m), 7.69 (1H, dd, J = 7.5, 7.5 Hz), 8.19 (1H,
d, J = 7.5 Hz), 8.36 (1H, d, J = 7.5 Hz), 8.46 (1H, d, J = 6.0 Hz), 8.65
(1H, d, J = 6.0 Hz), 9.32 (1H, s); 13C NMR (126 MHz, CDCl 3) d
20.7, 32.0, 34.8, 35.3, 41.7, 46.3, 53.8, 117.7, 125.9, 129.1, 131.9,
133.0, 133.6, 133.9, 144.9, 153.2; LC–MS (ESI+) m/z 346 (M+H);
HRMSm/z calcd for C18H24N3O2S (M+H) 346.1584, found 346.1588.
5.1.17. 5-(2,8-Diazaspiro[5.5]undecan-2-ylsulfonyl)isoquinoline
(25)
Prepared as described for 20 starting from 7 and 5-isoquinoline
sulfonyl chloride to give 25 as a colourless oil (71% over 2 steps). 1H
NMR (500 MHz, CDCl3) d 1.19–1.26 (2H, m), 1.37–1.41 (3H, m),
1.47–1.53 (1H, m), 1.61–1.68 (2H, m), 1.75–1.88 (1H, br s), 2.50
(1H, d, J = 12.5 Hz), 2.60–2.67 (2H, m), 2.79–2.85 (1H, m), 3.02
(1H, d, J = 12.0 Hz), 3.11 (1H, d, J = 12.0 Hz), 3.13–3.24 (2H, m),
7.64–7.77 (1H, m), 8.20 (1H, d, J = 8.2 Hz), 8.40 (1H, dd, J = 7.5,
1.0 Hz), 8.52 (1H, d, J = 6.0 Hz), 8.69 (1H, d, J = 6.0 Hz), 9.35 (1H,
d, J = 1.0 Hz); 13C NMR (126 MHz, CDCl3) d 20.8, 22.1, 32.2, 32.8,
33.4, 46.3, 46.5, 52.5, 53.9, 117.8, 126.0, 129.1, 131.9, 133.0,
133.5, 134.1, 145.1, 153.2; LC–MS (ESI+) m/z 346 (M+H); HRMS
m/z calcd for C18H24N3O2S, 346.1584, found 346.1597.
5.1.18. 5-(1,8-Diazaspiro[4.5]decan-1-ylsulfonyl)isoquinoline
(26)
Prepared as described for 20 starting from 5 and 5-isoquinoline
sulfonyl chloride to give 26 as a yellow oil (2% over 2 steps). 1H
NMR (500 MHz, CDCl3) d 1.67–1.72 (2H, m), 1.80–1.93 (2H, m),
2.05 (2H, dd, J = 13.0, 7.0 Hz), 2.58–2.70 (4H, m), 3.11–3.16 (2H,
m), 3.38 (2H, dd, J = 7.0, 7.0 Hz), 7.71 (1H, dd, J = 7.5, 7.5 Hz),
8.20–8.21 (1H, m), 8.41 (1H, dd, J = 7.5, 1.0 Hz), 8.64 (1H, d,
J = 6.0 Hz), 8.71 (1H, d, J = 6.0 Hz), 9.36 (1H, m); 13C NMR
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127.7, 129.2, 131.9, 132.7, 133.3, 144.8, 153.1; LC–MS (ESI+) m/z
332 (M+H); HRMS m/z calcd for C17H22N3O2S (M+H) 332.1427,
found 332.1439.
5.1.19. 6-(3-Azaspiro[5.5]undecan-3-yl)-9H-purine (27)
Prepared as described for 11 starting from 3-azaspiro[5.5]unde-
cane and 6-chloropurine to give 27 as a white solid (65%). mp 266–
268 C; 1H (500 MHz, DMSO-d6) d 1.40–1.46 (14H, m), 4.09–4.18
(4H, br m), 8.07 (1H, s), 8.16 (1H, s), 12.91 (1H, s); 13C (126 MHz,
DMSO-d6) d 21.5, 26.8, 31.6, 36.3, 36.4, 40.4, 119.3, 138.1, 151.7,
152.3, 153.6; LC–MS (ESI+) m/z 272 (M+H); HRMS m/z calcd for
C15H22N5 (M+H) 272.1870, found 272.1875.
5.1.20. 9-(9H-Purin-6-yl)-1-oxa-9-azaspiro[5.5]undecane (28)
Prepared as described for 11 starting from 1-oxa-9-azaspi-
ro[5.5]undecane and 6-chloropurine to give 28 as an off-white
solid (14%). mp 267 C (dec); 1H NMR (500 MHz, DMSO-d6) d
1.37–1.48 (6H, m), 1.55–1.62 (2H, m), 1.87–1.92 (2H, m), 3.41–
3.55 (2H, m), 3.59–3.65 (2H, m), 4.76–5.07 (2H, m), 8.08 (1H, s),
8.17 (1H, s), 12.94 (1H, s); 13C (126 MHz, DMSO-d6) d 18.8, 26.3,
34.3, 35.5, 40.8, 60.5, 70.1, 119.2, 138.2, 151.8, 152.3, 153.6; LC–
MS (ESI+) m/z 274 (M+H); HRMS m/z calcd for C14H20N5O (M+H)
274.1662, found 274.1660.
5.1.21. 9-(9H-Purin-6-yl)-2-oxa-9-azaspiro[5.5]undecane (29)
Prepared as described for 11 starting from 2-oxa-9-azaspi-
ro[5.5]undecane and 6-chloropurine to give 29 as a white solid
(60%). mp 268–269 C; 1H NMR (500 MHz, DMSO-d6) d 1.44–1.54
(8H, m), 3.41 (2H, s), 3.53–3.55 (2H, m), 4.10–4.19 (4H, br m),
8.08 (1H, s), 8.17 (1H, s), 12.97 (1H, s); 13C (126 MHz, DMSO-d6)
d 22.0, 31.7, 33.4, 33.5, 40.4, 68.5, 75.4, 119.2, 138.2, 151.8,
152.3, 153.6; LC–MS (ESI+) m/z 274 (M+H); HRMS m/z calcd for
C14H20N5O (M+H) 274.1662, found 274.1669.
5.1.22. tert-Butyl 9-benzyl-3-hydroxy-1,9-diazaspiro[5.5]
undecane-1-carboxylate (31) and tert-butyl 9-benzyl-4-
hydroxy-1,9-diazaspiro[5.5]undecane-1-carboxylate (32)
A mixture of 0.5 M 9-BBN in THF (2.6 mL, 1.31 mmol) and tert-
butyl 9-benzyl-1,9-diazaspiro[5.5]undec-3-ene-1-carboxylate 3017
(130 mg, 0.43 mmol) was heated to reﬂux for 3 h. The reaction
mixture was cooled to 0 C and 1 M NaOH aq (1.3 mL) was added
followed by 15% w/v H2O2 (65 lL) ensuring that the temperature
did not exceed 10 C. The reaction mixture was stirred at 0 C for
30 min then extracted with Et2O (3  10 mL). The combined organ-
ic extracts were dried and concentrated. Flash column chromatog-
raphy eluting with 3% 2 M NH3 in MeOH/CH2Cl2 gave 31 as a
yellow oil (48 mg, 31%) and 32 as a yellow oil (50 mg, 32%). 31:
1H NMR (500 MHz, CDCl3) d 1.49 (9H, s), 1.52–1.69 (4H, m),
1.83–1.96 (3H, m), 2.40–2.47 (2H, m), 2.48–2.55 (2H, m), 2.65–
2.74 (2H, m), 3.48 (1H, dd, J = 14.5, 6.5 Hz), 3.52 (2H, s), 3.68 (1H,
dd, J = 14.0, 4.0 Hz), 3.82–3.87 (1H, m), 7.24–7.28 (1H, m), 7.30–
7.36 (4H, m,); 13C NMR (126 MHz, CDCl3) d 27.7, 28.5, 30.4, 33.7,
47.5, 50.2, 50.3, 56.9, 63.0, 66.4, 79.9, 126.9, 128.2, 129.1, 156.2,
one quaternary carbon not detected; LC–MS (ESI+) m/z 361
(M+H); HRMS m/z calcd for C21H33N2O3 (M+H) 361.2486, found
361.2496. 32: 1H NMR (500 MHz, CDCl3) d 1.38–1.46 (2H, m),
1.49 (9H, s), 1.55–1.61 (1H, m), 1.65–1.71 (1H, m), 1.94–2.01
(1H, m), 2.09 (1H, dd, J = 13.0, 4.5 Hz), 2.32–2.39 (1H, m), 2.43–
2.47 (2H, m), 2.52–2.56 (2H, m), 3.02 (1H, ddd, J = 13.0, 11.0,
2.0 Hz), 3.21 (1H, ddd, J = 14.0, 10.0, 5.0 Hz), 3.52 (2H, d,
J = 6.0 Hz), 3.94 (1H, ddd, J = 14.0, 5.0, 5.0 Hz), 4.04 (1H, dddd,
J = 10.0, 10.0, 5.0, 5.0 Hz), 7.24–7.28 (1H, m), 7.30–7.35 (4H, m);
13C NMR (126 MHz, CDCl3) d 28.5, 33.3, 34.7, 36.5, 40.1, 42.7,
49.5, 50.5, 57.4, 63.0, 65.1, 79.7, 127.0, 128.2, 129.2, 138.8, 155.5;LC–MS (ESI+) m/z 361 (M+H); HRMS m/z calcd for C21H33N2O3
(M+H) 361.2486, found 361.2492.
5.1.23. 9-(9H-Purin-6-yl)-1,9-diazaspiro[5.5]undecan-3-ol (33)
A mixture of (HCO2)NH4 (175 mg, 2.78 mmol), 31 (200 mg,
0.57 mmol) and Pd/C (20 mg, 10 wt%) in MeOH (3 mL) under N2
was stirred at reﬂux for 5 h. The mixture was cooled to rt and
passed through celite to remove palladium. Puriﬁcation by ion ex-
change chromatography on acidic resin eluting with 2 M NH3 in
MeOH gave tert-butyl 3-hydroxy-1,9-diazaspiro[5.5]undecane-1-
carboxylate as a clear oil (120 mg, 86%). 1H NMR (500 MHz, CDCl3)
d 1.47 (9H, s), 1.54–1.64 (4H, m), 1.87–1.97 (2H, m), 2.13 (2H, br s),
2.59–2.68 (2H, m), 2.76–2.80 (2H, m), 2.90–2.97 (2H, m), 3.41 (1H,
dd, J = 14.0, 7.0 Hz), 3.70 (1H, dd, J = 14.0, 4.0 Hz), 3.85–3.89 (1H,
m); 13C NMR (126 MHz, CDCl3) d 27.1, 28.1, 29.6, 33.9, 34.3, 42.7,
42.8, 46.9, 56.7, 65.6, 79.4, 155.5; LC–MS (ESI+) m/z 271 (M+H);
HRMS m/z calcd for C10H19N2O3 (M–tBu) 215.1390, found
215.1398. A mixture of Et3N (0.16 mL, 1.55 mmol), tert-butyl 3-hy-
droxy-1,9-diazaspiro[5.5]undecane-1-carboxylate (61 mg,
0.23 mmol) and 6-chloropurine (35 mg, 0.23 mmol) in nBuOH
(1 mL) was heated to 100 C for 16 h. The mixture was cooled
and concentrated to dryness. Preparative TLC, eluting with 5%
2 M NH3 in MeOH/CH2Cl2 gave tert-butyl 3-hydroxy-9-(9H-purin-
6-yl)-1,9-diazaspiro[5.5]undecane-1-carboxylate as an off-white
solid (41 mg, 46%). A portion of this material (20 mg, 0.052 mmol)
was dissolved in MeOH (1 mL) and 4 M HCl in dioxane (0.13 mL,
0.52 mmol) was added, followed by stirring at rt for 16 h. The mix-
ture was concentrated and puriﬁed by ion exchange chromatogra-
phy on acidic resin eluting with 2 M NH3 in MeOH to give 33 as a
white solid (12 mg, 0.04 mmol, 80%). mp = 189 C (dec); 1H NMR
(500 MHz, DMSO-d6) d 1.21–1.29 (1H, m), 1.40–1.48 (3H, m),
1.52–1.63 (2H, m), 1.66–1.74 (1H, m), 1.75–1.82 (1H, m), 2.39–
2.49 (1H, dd, J = 13.0, 8.0 Hz), 2.78 (1H, dd, J = 13.0, 3.5 Hz), 3.26–
3.44 (1H, m), 3.74–3.92 (2H, br m), 4.45–4.75 (2H, br m), 8.08
(1H, s), 8.17 (1H, s); 13C NMR (126 MHz, DMSO-d6) d 29.1, 33.1,
34.8, 37.0, 41.7, 47.6, 49.1, 66.8, 119.2, 138.2, 151.8, 152.3, 153.5;
LC–MS (ESI+) m/z 289 (M+H); Rt = 0.71, Purity = 90%; HRMS m/z
calcd for C14H21N60 (M+H) 289.1761, found 289.1771.
5.1.24. 9-(Isoquinolin-5-ylsulfonyl)-1,9-diazaspiro[5.5]
undecan-3-ol (34)
A mixture of (HCO2)NH4 (175 mg, 2.78 mmol), 31 (200 mg,
0.57 mmol) and Pd/C (20 mg, 10 wt%) in MeOH (3 mL) was stirred
at reﬂux for 5 h. The mixture was cooled to rt and passed through
celite to remove palladium. Puriﬁcation by ion exchange chroma-
tography on acidic resin eluting with 2 M NH3 in MeOH gave
tert-butyl 3-hydroxy-1,9-diazaspiro[5.5]undecane-1-carboxylate
as a clear oil. A mixture of Et3N (0.41 mL, 2.95 mmol), tert-butyl
3-hydroxy-1,9-diazaspiro[5.5]undecane-1-carboxylate (160 mg,
0.59 mmol) and 5-isoquinoline sulfonyl chloride (231 mg,
0.88 mmol) in CH2Cl2 (3 mL) was stirred at rt for 4 h. The reaction
was quenched with H2O (5 mL) and washed with H2O (3  5 mL).
The organic layer was dried and concentrated. Preparative TLC
eluting with 5% MeOH/ CH2Cl2 gave tert-butyl 3-hydroxy-9-(iso-
quinolin-5-ylsulfonyl)-1,9-diazaspiro[5.5]undecane-1-carboxylate
as a yellow oil (100 mg). 4 M HCl in dioxane (0.50 mL, 2.0 mmol)
was added to a solution of this material in MeOH (2 mL) and stirred
at r. t. for 48 h. The mixture was concentrated and puriﬁed by ion
exchange chromatography on acidic resin eluting with 2 M NH3 in
MeOH, followed by preparative TLC eluting with 5% MeOH/CH2Cl2,
to give 34 as a colourless oil (30 mg, 14% over 2 steps); 1H NMR
(500 MHz, CDCl3) d 1.25–1.31 (1H, m), 1.56–1.72 (6H, m), 1.74–
1.81 (1H, m), 2.58 (1H, dd, J = 13.5, 6.5 Hz) 2.83 (1H, dd, J = 13.5,
3.0 Hz), 3.06–3.14 (2H, m), 3.40–3.45 (2H, m), 3.65 (1H, dddd,
J = 6.5, 6.5, 3.0, 3.0 Hz), 7.73 (1H, dd, J = 7.5, 7.5 Hz), 8.23 (1H, d,
J = 7.5 Hz), 8.40 (1H, dd, J = 7.5, 1.0 Hz), 8.53 (1H, d, J = 6.0 Hz),
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27.5, 32.5, 33.2, 34.8, 40.9, 41.1, 46.1, 47.8, 65.8, 117.3, 125.4,
128.7, 131.5, 132.4, 133.2, 133.6, 144.5, 152.8; LC–MS (ESI+) m/z
362 (M+H); HRMS m/z calcd for C18H24N3O3S (M+H) 362.1533,
found 362.1522.
5.1.25. 9-(9H-Purin-6-yl)-1,9-diazaspiro[5.5]undecan-4-ol (35)
Prepared as described for 33 starting from 32 and 6-chloropu-
rine to give 35 as a colourless oil (36% over 3 steps). mp = 198 C
(dec); 1H NMR (500 MHz, CD3OD) d 1.25 (1H, dd, J = 12.5,
10.5 Hz), 1.40 (1H, dddd, J = 12.0, 12.0, 12.0, 4.5 Hz), 1.66–1.70
(1H, m), 1.72–1.79 (1H, m), 1.80–1.82 (2H, m), 1.94–1.97 (1H,
m), 2.09 (1H, dd, J = 12.5, 3.5 Hz), 2.83–2.88 (1H, m), 2.95–2.98
(1H, m), 3.87–3.93 (1H, m), 4.21–4.33 (4H, m), 7.99 (1H, s), 8.20
(1H, s); 13C NMR (126 MHz, CD3OD) d 31.9, 35.0, 38.2, 38.9, 40.8,
40.9, 43.3, 51.7, 64.4, 118.8, 137.8, 150.9, 151.7, 153.6; LC–MS
(ESI+) m/z 289 (M+H); HRMS m/z calcd for C14H21N6O (M+H)
289.1771, found 289.1778.
5.1.26. 9-(Isoquinolin-5-ylsulfonyl)-1,9-diazaspiro[5.5]
undecan-4-ol (36)
Prepared as described for 34 starting from 32 and 5-isoquino-
line sulfonyl chloride to give 36 as a colourless oil (36% over 3
steps). 1H NMR (500 MHz, CDCl3) d 1.00–1.08 (1H, m), 1.14–1.21
(1H, m), 1.44–1.60 (2H, m), 1.68–1.82 (3H, m), 1.87–1.91 (1H,
m), 2.56–2.61 (1H, m), 2.86–2.88 (1H, m), 3.04–3.12 (2H, m),
3.40–3.45 (2H, m), 3.80–3.84 (1H, m), 7.71 (1H, dd, J = 7.5,
7.5 Hz), 8.21 (1H, d, J = 7.5 Hz), 8.37 (1H, d, J = 7.5 Hz), 8.52 (1H,
d, J = 6.0 Hz), 8.67 (1H, d, J = 6.0 Hz), 9.35 (1H, s); 13C NMR
(126 MHz, CDCl3) d 32.1, 36.9, 38.9, 39.3, 41.3, 41.4, 46.4, 50.7,
65.4, 117.8, 125.9, 129.2, 132.0, 133.0, 133.6, 133.9, 145.0, 153.2;
LC–MS (ESI+) m/z 362 (M+H); HRMS m/z calcd for C18H24N3O3S
(M+H) 362.1533, found 362.1528.
5.1.27. 1,9-Dibenzyl-1,9-diazaspiro[5.5]undec-3-en-2-one (38)
Acryloyl chloride (1.33 mL, 16.6 mmol) was added to a solution
of 4-allyl-N,1-dibenzylpiperidin-4-amine 3717 (3.80 g, 11.9 mmol),
Et3N (4.95 mL, 35.6 mmol) and DMAP (108 mg, 0.89 mmol) in CH2-
Cl2 (30 mL) at 0 C. The reaction mixture was stirred for 16 h. Fur-
ther acryloyl chloride (0.48 mL, 5.94 mmol) was added. After
stirring for 16 h, the reaction mixture was diluted with H2O
(25 mL) and extracted with CH2Cl2 (3  20 mL). The extracts were
dried and concentrated. Ion exchange chromatography on acidic
resin, eluting with 2 M NH3 in MeOH, gave N-(4-allyl-1-benzylpi-
peridin-4-yl)-N-benzylacrylamide as an orange oil (4.05 g,
10.8 mmol, 91%). 1H NMR (500 MHz, CDCl3) d 1.83–1.91 (2H, m),
2.19–2.24 (2H, m), 2.52–2.54 (2H, m), 2.69–2.71 (2H, m), 2.96
(2H, d, J = 12.0 Hz), 3.47 (2H, s), 4.57 (2H, s), 5.09–5.17 (2H, m),
5.54 (1H, dd, J = 8.0, 4.5 Hz), 5.75–5.84 (1H, m), 6.31–6.34 (2H,
m), 7.22–7.32 (8H, m), 7.37–7.42 (2H, m); 13C NMR (126 MHz,
CDCl3) d 33.0, 34.8, 48.9, 49.6, 61.3, 62.5, 118.1, 125.2, 126.5,
126.6, 126.9, 127.7, 128.4, 128.6, 131.1, 133.5, 137.7, 138.9,
168.5; LC–MS (ESI+) m/z 375 (M+H); HRMS m/z calcd for
C25H31N2O (M+H) 375.2431, found 375.2441. Ti(OiPr)4 (3.00 mL,
11.9 mmol) was added to N-(4-allyl-1-benzylpiperidin-4-yl)-
N-benzylacrylamide (4.45 g, 11.9 mmol) in CH2Cl2 (200 mL) and
heated to reﬂux for 1 h. Grubbs I catalyst (389 mg, 0.474 mmol)
was added and reﬂux was continued for 3 h. DMSO (0.84 mL)
was added and the mixture was stirred for 16 h, then concentrated.
Flash column chromatography, eluting with 50% EtOAc–hexanes,
gave 38 (3.11 g, 9.01 mmol, 76%) as an oil. 1H NMR (500 MHz,
CDCl3) d 1.62–1.65 (2H, m,), 1.98–2.08 (4H, m), 2.54 (2H, dd,
J = 4.5, 1.5 Hz), 2.73–2.75 (2H, m), 3.49 (2H, s), 4.81 (2H, s), 6.11
(1H, dt, J = 9.5, 1.5 Hz), 6.49 (1H, dt, J = 9.5, 4.5 Hz), 7.19–7.34
(10H, m); 13C NMR (126 MHz, CDCl3) d 31.6, 33.5, 43.1, 49.8,
58.1, 62.9, 125.4, 126.5, 126.6, 127.2, 128.3, 128.4, 129.1, 136.5,137.8, 140.0, 165.5; LC–MS (ESI+) m/z 347 (M+H); HRMS m/z calcd
for C23H27N2O (M+H) 347.2118, found 347.2112.
5.1.28. 1,9-Dibenzyl-4-phenyl-1,9-diazaspiro[5.5]undecan-2-
one (39)
Freshly prepared PhMgBr (5.9 mL, 1 M in THF) was added
slowly to a suspension of CuBr.SMe2 (607 mg, 2.96 mmol) in THF
(12 mL) at 40 C. The bright yellow solution was stirred for
30 min at 40 C followed by addition of 38 (205 mg, 0.59 mmol)
in THF (3 mL) and TMSCl (1.12 mL, 8.85 mmol) at 78 C. The mix-
ture was stirred at 78 C for 1 h, then diluted with NH4Cl (15 mL)
and extracted with Et2O (3  20 mL). The combined extracts were
dried and concentrated. Ion exchange chromatography on acidic
resin, eluting with 2 M NH3 in MeOH, gave 39 (210 mg, 0.50 mmol,
84%) as a yellow oil. 1H NMR (500 MHz, CDCl3) d 1.34–1.36 (1H, m),
1.69 (1H, dd, J = 13.5, 13.5 Hz), 1.82–1.85 (1H, m), 2.12–2.26 (4H,
m), 2.69–2.73 (3H, m), 2.85–2.90 (2H, m), 3.15–3.22 (1H, m),
3.48 (2H, s), 4.45 (1H, d, J = 16.0 Hz), 5.18 (1H, d, J = 16.0 Hz),
7.20–7.34 (13H, m), 7.39–7.42 (2H, m); 13C NMR (126 MHz, CDCl3)
d 32.2, 33.9, 38.0, 38.3, 40.2, 44.6, 49.6, 50.2, 59.1, 62.9, 126.3,
126.4, 126.7, 127.0, 127.2, 128.3, 128.3, 128.9, 129.0, 138.1,
139.4, 143.7, 170.8; LC–MS (ESI+) m/z 425 (M+H); HRMS m/z calcd
for C29H33N2O (M+H) 425.2587, found 425.2608.
5.1.29. 1,4,9-Tribenzyl-1,9-diazaspiro[5.5]undecan-2-one (40)
1 M BnMgCl in Et2O (7.23 mL, 7.23 mmol) was added slowly to
a suspension of CuBr.SMe2 (740 mg, 3.61 mmol) in THF (20 mL)
under N2 at 40 C to give a bright yellow solution. After stirring
for 30 min at 40 C, 38 (250 mg, 0.72 mmol) in THF (5 mL) was
added. The mixture was stirred at rt for 16 h then quenched with
NH4Cl (25 mL). The mixture was extracted with Et2O (3  20 mL),
and the extracts were dried and concentrated. Ion exchange chro-
matography on acidic resin eluting with 2 M NH3 in MeOH gave 40
as a yellow oil (302 mg, 0.68 mmol, 95%). 1H NMR (500 MHz,
CDCl3) d 1.10–1.20 (1H, m), 1.24 (1H, d, J = 11.0 Hz), 1.59–1.65
(1H, m), 1.88–1.96 (1H, m), 2.00–2.25 (6H, m), 2.43–2.53 (1H,
m), 2.58–2.70 (4H, m), 2.71–2.76 (1H, m), 3.44 (2H, s), 4.34 (1H,
d, J = 16.0 Hz), 5.12 (1H, d, J = 16.0 Hz), 7.13–7.23 (5H, m), 7.23–
7.38 (10 H, m);. 13C NMR (126 MHz, CDCl3) d 29.7, 32.1, 36.6,
37.8, 39.1, 42.5, 44.5, 49.6, 50.1, 58.9, 62.8, 126.2, 126.4, 126.4,
126.6, 127.2, 128.3, 128.5, 129.0, 129.0, 138.0, 139.0, 139.4,
171.1; LC–MS (ESI+) m/z 439 (M+H); HRMS m/z calcd for
C30H35N2O (M+H) 439.2744, found 439.2727.
5.1.30. 6-(4-Phenyl-1,9-diazaspiro[5.5]undecan-9-yl)-9H-purine
(41)
LiAlH4 (1 M in toluene, 1.15 mL) was added to a solution of 39
(122 mg, 0.290 mmol) in THF (2 mL) at 0 C. The reaction mixture
was heated to 50 C for 4 h then cooled to rt H2O (0.21 mL) and
20% NaOH aq (0.21 mL) were added and the reaction mixture
was stirred for 30 mins, followed by a second addition of H2O
(0.63 mL). The mixture was ﬁltered and the ﬁltrate was absorbed
on to silica gel. Flash column chromatography, eluting with 30%
EtOAc–hexanes, gave 1,9-dibenzyl-4-phenyl-1,9-diazaspiro[5.5]-
undecane as a clear oil (74 mg, 0.18 mmol, 63%). 1H NMR
(500 MHz, CDCl3) d 1.37–1.50 (2H, m), 1.63–1.66 (1H, m), 1.69–
1.78 (1H, m), 1.88–1.96 (1H, m), 1.97–2.01 (1H, m), 2.21–2.38
(4H, m), 2.67–2.73 (3H, m), 2.75–2.90 (2H, m), 3.33 (1H, d,
J = 14.0 Hz), 3.55 (2H, s), 4.19 (1H, d, J = 14.0 Hz), 7.21–7.29 (5H,
m), 7.30–7.37 (8H, m), 7.37–7.41 (2H, m); 13C NMR (126 MHz,
CDCl3) d 26.1, 31.7, 36.9, 37.8, 39.6, 46.2, 49.6, 50.0, 51.7, 54.5,
63.2, 126.1, 126.4, 126.9, 126.9, 128.1, 128.2, 128.2, 128.4, 129.1,
138.5, 141.8, 146.9; LC–MS (ESI+) m/z 411 (M+H); HRMS m/z
calcd for C29H35N2 (M+H) 411.2795, found 411.2779. A mixture
of 1,9-dibenzyl-4-phenyl-1,9-diazaspiro[5.5]undecane (167 mg,
0.40 mmol) and Pd/C (17 mg) in MeOH (5 mL) was heated to reﬂux
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was concentrated in vacuo to give crude 4-phenyl-1,9-diazaspi-
ro[5.5]undecane as a yellow oil (76 mg, 0.33 mmol, 82%). A portion
of the crude material (37 mg, 0.16 mmol), 6-chloropurine (24 mg,
0.16 mmol) and Et3N (0.11 mL, 0.80 mmol) in nBuOH (1 mL) was
stirred at 100 C for 2 h. The mixture was cooled to rt and concen-
trated. Preparative HPLC gave 41 as a pale yellow solid (15 mg,
0.04 mmol, 27%). mp 217–219 C; 1H NMR (500 MHz, DMSO-d6) d
1.29–1.35 (1H, m), 1.40–1.59 (4H, m), 1.70 (2H, dd, J = 12.5,
3.0 Hz), 2.01–2.10 (1H, m), 2.85–2.89 (3H, m) 3.72–3.97 (2H, brd
m), 4.55–4.81 (2H, brd m), 7.15–7.19 (1H, m), 7.21–7.24 (2H, m),
7.26–7.31 (2H, m), 8.08 (1H, s), 8.18 (1H, s); 13C NMR (126 MHz,
DMSO-d6) d 30.5, 34.4, 37.1, 39.0, 39.8, 40.1, 44.6, 49.8, 118.7,
125.8, 126.7, 128.3, 137.7, 146.9, 151.3, 151.8, 153.1; LC–MS
(ESI+) m/z 349 (M+H); HRMS m/z calcd for C20H25N6 (M+H)
349.2135, found 349.2130.
5.1.31. 6-(4-Benzyl-1,9-diazaspiro[5.5]undecan-9-yl)-9H-purine
(42)
1 M LiAlH4 in toluene (0.88 mL) was added to a solution of 40
(100 mg, 0.22 mmol) in THF (3 mL) at 0 C. The mixture was heated
to 50 C for 3 h then cooled to rt H2O (120 lL) followed by 20%
NaOH aq (120 lL) were added and stirred for 30 min, followed
by a second addition of H2O (360 lL). The mixture was ﬁltered
and the ﬁltrate was absorbed onto silica gel and puriﬁed by ﬂash
column chromatography, eluting with 20% EtOAc/hexane, to give
1,4,9-tribenzyl-1,9-diazaspiro[5.5]undecane as a yellow oil
(75 mg, 0.18 mmol, 80%); 1H NMR (500 MHz, CDCl3) d 0.97–1.03
(1H, m), 1.16–1.28 (1H, m), 1.31–1.43 (2H, m), 1.74–1.85 (3H,
m), 1.95–2.03 (1H, m), 2.09–2.17 (2H, m), 2.27–2.34 (1H, m),
2.44–2.59 (4H, m), 2.63–2.71 (1H, m), 2.72–2.81 (1H, m), 3.29
(1H, d, J = 14.0 Hz), 3.52 (2H, s), 4.08 (1H, d, J = 14.0 Hz), 7.14–
7.18 (2H, m), 7.19–7.24 (2H, m), 7.27–7.37 (11H, m); 13C NMR
(126 MHz, CDCl3) d 26.1, 29.9, 32.8, 36.3, 38.2, 43.5, 45.3, 49.0,
49.4, 50.9, 53.7, 62.7, 125.3, 125.8, 126.4, 127.6, 127.6, 128.4,
128.6, 128.6, 138.0, 140.1, 141.4; LC–MS (ESI+) m/z 425 (M+H);
HRMS m/z calcd for C30H37N2 (M+H) 425.2951, found 425.2971.
Pd/C (17 mg) was added to 1,4,9-tribenzyl-1,9-diazaspi-
ro[5.5]undecane (105 mg, 0.24 mmol) in MeOH (3 mL) and the
ﬂask was evacuated with air and reﬁlled with 1 atm H2 (x3). The
mixture was heated to 50 C for 4 days. The cooled mixture was ﬁl-
tered and the ﬁltrate was concentrated to give a yellow oil that was
used directly in next reaction. Et3N (0.17 mL, 1.25 mmol) and 6-
chloropurine (38 mg, 0.25 mmol) were added to a solution of the
crude material from the previous step (61 mg, 0.24 mmol) in n-
BuOH (1 mL) and the mixture was heated to 100 C for 16 h. The
mixture was cooled to rt and concentrated. Flash column chroma-
tography eluting with 10% MeOH/ CH2Cl2, followed by preparative
TLC eluting with 10% MeOH/CH2Cl2, gave 42 as a pale yellow solid
(30 mg, 33% over 2 steps); mp = 203 C (dec); 1H NMR (500 MHz,
CDCl3) d 0.93–1.01 (1H, m), 1.08 (1H, dddd, J = 12.5, 12.5, 12.5,
4.5 Hz), 1.50–1.56 (1H, m), 1.58–1.74 (4H, m), 1.85–2.02 (2H, m),
2.44–2.57 (2H, m), 2.81 (1H, ddd, J = 13.0, 13.0, 3.5 Hz), 2.91–2.96
(1H, m), 3.90–4.10 (2H, br m), 4.48–4.72 (2H, br m), 7.08–7.23
(3H, m), 7.23–7.30 (2H, m), 7.93 (1H, s), 8.35 (1H, s); 13C NMR
(126 MHz, CDCl3) d 31.2, 33.4, 33.9, 40.6, 40.9, 40.9, 43.9, 44.1,
50.3, 119.6, 125.9, 128.2, 129.1, 136.6, 140.2, 151.2, 151.5, 153.9;
LC–MS (ESI+) m/z 363 (M+H); HRMS m/z calcd for C21H26N6Na
(M+H) 385.2111, found 385.2099.
5.1.32. 1,3,9-Tribenzyl-1,9-diazaspiro[5.5]undec-3-en-2-one
(43)
Oxalyl chloride (0.070 mL, 0.87 mmol), was added to a solution
of 2-benzylacrylic acid (170 mg, 0.79 mmol) in CH2Cl2 (2 mL) fol-
lowed by one drop of DMF. The mixture was stirred at rt for 2 h
and then concentrated to give 2-benzylacryloyl chloride. Et3N(0.36 mL, 2.65 mmol) was added to a solution of 3717 (170 mg,
0.53 mmol), 2-benzylacryloyl chloride (171 mg, 0.80 mmol) and
DMAP (5 mg, 0.04 mmol) in CH2Cl2 (3 mL). The mixture was stirred
at rt for 16 h, then diluted with H2O (5 mL) and extracted with
CH2Cl2 (3  10 mL). The combined extracts were dried and con-
centrated. Flash column chromatography, eluting with 30%
EtOAc–hexanes, gave N-(4-allyl-1-benzylpiperidin-4-yl)-N,2-
dibenzylacrylamide as a yellow oil (120 mg, 0.26 mmol, 49%). 1H
NMR (500 MHz, CDCl3) d 1.97–2.01 (2H, m), 2.25–2.37 (4H, m),
2.59–2.60 (2H, m), 2.87 (2H, d, J = 7.5 Hz), 3.46 (2H, s), 3.52 (2H,
s), 4.49 (2H, s), 4.72 (1H, s), 5.04–5.07 (3H, m), 5.62 (1H, ddt,
J = 17.5, 10.5, 7.5 Hz), 7.13–7.35 (15H, m); 13C NMR (126 MHz,
CDCl3) d 33.2, 36.0, 40.7, 50.0, 50.7, 61.7, 62.9, 113.7, 118.3,
126.2, 126.6, 126.8, 127.0, 128.1, 128.5, 128.5, 129.1, 126.9,
134.1, 137.6, 138.2, 140.4, 146.7, 174.6; LC–MS (ESI+) m/z 465.30
(M+H); HRMS m/z calcd for C32H36N2O (M+H) 465.2900;
found 465.2883. Ti(OiPr)4 (0.13 mL, 0.42 mmol), was added to N-
(4-allyl-1-benzylpiperidin-4-yl)-N,2-dibenzylacrylamide (100 mg,
0.21 mmol) in CH2Cl2 (10 mL) and heated to reﬂux for 1 h. Hov-
eyda-Grubbs II catalyst (389 mg, 0.47 mmol) was added and reﬂux
was continued for 30 h. DMSO (0.11 mL) was added and the mix-
ture was stirred for 16 h, then concentrated. Flash column chroma-
tography, eluting with 50% EtOAc–hexanes, gave 43 (60 mg,
0.14 mmol, 66%). 1H NMR (500 MHz, CDCl3) d 1.58–1.61 (2H, m),
1.96 (2H, ddd, J = 12.5, 12.5, 4.0 Hz), 2.05 (2H, ddd, J = 12.5, 12.5,
2.0 Hz), 2.46–2.53 (2H, m), 2.71–2.73 (2H, m), 3.47 (2H, s), 3.70–
3.71 (2H, s), 4.80 (2H, s), 6.01 (1H, dd, J = 4.5, 4.5 Hz), 7.19–7.35
(15H, m); 13C NMR (126 MHz, CDCl3) d 31.4, 33.6, 36.8, 43.7,
49.8, 57.9, 62.9, 126.1, 126.5, 126.6, 127.1, 128.2, 128.3, 128.4,
129.1, 129.4, 131.4, 135.5, 137.19, 139.6, 140.1, 166.0; LC–MS
(ESI+) m/z 437.17 (M+H); HRMS m/z calcd for C30H33N2O (M+H)
437.2587, found 437.2600.
5.1.33. 6-(3-Benzyl-1,9-diazaspiro[5.5]undecan-9-yl)-9H-purine
(45)
A mixture of 43 (40 mg, 0.09 mmol) and Pd/C (4 mg) in EtOH
(1 mL) and THF (1 mL) with a drop of 1 M HCl was stirred at
30 C under H2 (1 atm) for 48 h. The mixture was ﬁltered and the
ﬁltrate was concentrated to give 1,3,9-tribenzyl-1,9-diazaspi-
ro[5.5]undecan-2-one HCl salt as a yellow oil (40 mg, 0.09 mmol).
The material was dissolved in THF (1.0 mL), LiAlH4 (1 M in THF,
0.36 mL, 0.36 mmol) was added and the mixture was heated to
50 C for 1 h, then cooled to rt The mixture was diluted with H2O
(14 lL) and 20% NaOH aq (14 lL) and stirred for 30 min, followed
by addition of H2O (41 lL). The mixture was ﬁltered and the ﬁltrate
was concentrated to give 1,3,9-tribenzyl-1,9-diazaspiro[5.5]unde-
cane as a yellow oil (26 mg, 0.06 mmol, 68%). 1H NMR (500 MHz,
CDCl3) d 1.21 (1H, ddd, J = 12.5, 3.5, 3.5 Hz), 1.29–1.38 (1H, m),
1.39–1.47 (1H, m), 1.50–1.58 (1H, m), 1.74–1.96 (4H, m), 2.07
(1H, ddd, J = 14.0, 10.5, 4.0 Hz), 2.23–2.40 (4H, m), 2.51 (1H, dd,
J = 13.5, 6.0 Hz), 2.57 (1H, ddd, J = 12.5, 3.5, 1.5 Hz), 2.66–2.74
(1H, m), 2.79–2.85 (1H, m), 3.42 (1H, d, J = 14.0 Hz), 3.54 (2H, s),
3.94 (1H, d, J = 14.0 Hz), 7.05–7.08 (2H, m), 7.14–7.18 (1H, m),
7.20–7.25 (3H, m), 7.27–7.36 (9H, m); 13C NMR (126 MHz, CDCl3)
d 26.0, 27.1, 31.0, 35.1, 35.8, 40.6, 49.6, 49.9, 51.9, 51.9, 53.6,
63.1, 125.6, 126.3, 127.0, 128.1, 128.2, 128.2, 129.0, 129.3, 129.3,
138.1, 140.6, 141.7; LC–MS (ESI+) m/z 425.21 (M+H); HRMS m/z
calcd for C30H37N2 (M+H) 425.2951; found 425.2970. A mixture
of 1,3,9-tribenzyl-1,9-diazaspiro[5.5]undecane (42 mg, 0.10 mmol)
and Pd/C (4 mg) in MeOH (4 mL) with 1 drop of 1 M HCl was stirred
at 40 C under H2 (1 atm) for 24 h. The mixture was ﬁltered and the
ﬁltrate was concentrated to give crude 3-benzyl-1,9-diazaspi-
ro[5.5]undecane HCl salt (44) as a yellow oil (30 mg, 0.094 mmol).
A mixture of crude 44 HCl salt (30 mg, 0.094 mmol), Et3N (60 lL,
0.47 mmol) and 6-chloropurine (14 mg, 0.094 mmol) in nBuOH
(0.5 mL) was stirred at 100 C for 2 h. The mixture was cooled to
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(1 mL) and the solid product was collected and washed with fur-
ther MeOH (2 mL). The white solid was dried to give 45 (13 mg,
0.04 mmol, 38%). mp 265 C (dec); 1H NMR (500 MHz, DMSO-d6)
d 1.15 (1H, ddd, J = 12.5, 12.5, 3.5 Hz), 1.23–1.30 (1H, m), 1.40–
1.56 (6H, m), 1.87 (1H, ddd, J = 13.5, 4.0, 4.0 Hz), 2.36–2.49 (3H,
m), 2.64 (1H, ddd, J = 13.0, 4.0, 2.0 Hz), 3.68–3.94 (2H, br m),
4.40–4.75 (2H, m), 7.13–7.18 (3H, m), 7.26 (2H, dd, J = 8.5,
6.5 Hz), 8.07 (1H, s), 8.16 (1H, s); 13C NMR (126 MHz, DMSO-d6)
d 26.7, 31.3, 36.7, 36.2, 39.4, 40.4, 40.7, 46.1, 49.2, 119.1, 126.1,
128.6, 129.3, 138.2, 141.1, 151.8, 152.3, 153.5; LC–MS (ESI+) m/z
363.20 (M+H); HRMS m/z calcd for C21H26N6 (M+H) 363.2291,
found 363.2294.
5.1.34. 1,9-Dibenzyl-3-phenyl-1,9-diazaspiro[5.5]undec-3-en-2-
one (46)
(COCl)2 (0.34 mL, 4.03 mmol) was added to a solution of 2-phe-
nyl acrylic acid (541 mg, 3.66 mmol) in CH2Cl2 (5 mL) under N2,
followed by the addition of one drop of DMF. The mixture was stir-
red for 2 h then concentrated to give crude 2-phenyl acryloyl chlo-
ride. EtNiPr2 (1.54 mL, 9.15 mmol) was added to a solution of 3717
(588 mg, 1.83 mmol), 2-phenyl acryloyl chloride (739 mg,
3.66 mmol) and DMAP (16 mg, 0.14 mmol) in CH2Cl2 (8 mL) under
N2. The mixture was stirred at rt for 16 h, then diluted with H2O
(15 mL). The mixture was extracted with CH2Cl2 (3  10 mL), and
the combined extracts were dried and concentrated. Gradient col-
umn chromatography using a Biotage KPNH column, eluting with
0–8% EtOAc/cyclohexane, gave N-(4-allyl-1-benzylpiperidin-4-yl)-
N-benzyl-2-phenylacrylamide as a yellow oil (689 mg, 1.53 mmol,
84%); 1H NMR (500 MHz, CDCl3) d 1.99 (2H, ddd, J = 12.5, 12.5,
4.0 Hz), 2.24 (2H, ddd, J = 12.0, 12.0, 2.5 Hz), 2.44–2.55 (2H, m),
2.68 (2H, ddd, J = 11.0, 3.5, 3.5 Hz), 3.05 (2H, d, J = 7.5 Hz), 3.46
(2H, s), 4.48 (2H, s), 5.09–5.18 (2H, m), 5.23 (1H, s), 5.38 (1H, s),
5.77 (1H, ddt, J = 17.5, 10.0, 7.5 Hz), 7.15–7.19 (2H, m), 7.20–7.37
(11H, m), 7.41–7.47 (2H, m); 13C NMR (126 MHz, CDCl3) d 33.3,
35.3, 50.0, 50.6, 61.9, 62.9, 113.2, 118.6, 125.8, 126.0, 126.7,
127.0, 128.2, 128.4, 128.4, 128.7, 129.1, 133.9, 136.0, 138.2,
139.8, 146.7, 173.0; LC–MS (ESI+) m/z 451 (M+H); HRMS m/z calcd
for C31H34N2ONa (M+H) 473.2563, found 473.2550. A solution of
N-(4-allyl-1-benzylpiperidin-4-yl)-N-benzyl-2-phenylacrylamide
(700 mg, 1.50 mmol) in toluene (10 mL) was ﬂushed with N2 for
20 min. Dichloro[1,3-bis(2-methylphenyl)-2-imidazolidinylid-
ene](2-isopropoxyphenyl-methylene) ruthenium(II) (30 mg,
0.05 mmol) was added and the mixture was heated to 80 C for
16 h. A further 2 portions of ruthenium catalyst (2  30 mg,
0.05 mmol) were added to the reaction over the 16 h period. The
mixture was cooled to rt and ﬁltered through basic ion exchange
resin washing with CH2Cl2 to remove the majority of the ruthe-
nium. The ﬁltrate was concentrated and puriﬁed by gradient chro-
matography, using a Biotage KPNH column eluting with 0–12%
EtOAc/cyclohexane, to give 46 as a yellow oil (481 mg, 1.13 mmol,
76%); 1H NMR (500 MHz, CDCl3) d 1.71–1.74 (22H, m, C3222H, m),
2.01–2.17 (4H, m), 2.69 (2H, d, J = 4.5 Hz), 2.76–2.78 (2H, m). 3.51
(2H, s), 4.88 (2H, s), 6.60 (1H, t, J = 4.5 Hz), 7.18–7.41 (14H, m),
7.49–7.51 (1H, m); 13C NMR (126 MHz, CDCl3) d 31.8, 33.8, 43.9,
49.9, 58.1, 62.9, 126.5, 126.9, 127.2, 127.6, 127.9, 128.3, 128.4,
128.7, 129.1, 133.1, 136.3, 137.0, 137.9, 140.2, 165.2; LC–MS
(ESI+) m/z 423.28 (M+H); HRMS m/z calcd for C29 H31N2O (M+H)
423.4321, found 423.2436.
5.1.35. 3-Phenyl-1,9-diazaspiro[5.5]undecane (47)
Pd/C (40 mg) and one drop of 1 M HCl were added to a solution
of 46 (405 mg, 0.95 mmol) in MeOH (10 mL) under N2. The ﬂask
was evacuated of air and reﬁlled with H2 to 1 atm (x3). The mixture
was heated to 40 C for 5 d. The mixture was ﬁltered and the ﬁl-
trate was concentrated. Ion exchange chromatography on acidicresin eluting with 2 M NH3 in MeOH gave 1,9-dibenzyl-3-phenyl-
1,9-diazaspiro[5.5]undecan-2-one as a yellow oil (245 mg) which
was used directly in the next reaction. 1 M LiAlH4 in THF
(2.93 mL, 2.93 mmol) was added to a solution of crude 1,9-diben-
zyl-3-phenyl-1,9-diazaspiro[5.5]undecan-2-one in THF (8 mL) un-
der N2 at rt, followed by AlCl3 (330 mg, 2.48 mmol). The mixture
was stirred at 50 C for 3 h then cooled to rt H2O (0.5 mL) and
20% NaOH aq (0.5 mL) were added. The suspension was stirred
for 30 min followed by further addition of H2O (1 mL). The mixture
was ﬁltered and the solids washed with Et2O (5 mL). The ﬁltrates
were concentrated to give 1,9-dibenzyl-3-phenyl-1,9-diazaspi-
ro[5.5]undecane as a yellow oil (137 mg) which was used directly
in the next reaction. (HCO2)NH4 (134 mg, 2.14 mmol) was added to
a mixture of the crude 1,9-dibenzyl-3-phenyl-1,9-diazaspi-
ro[5.5]undecane (137 mg) and Pd/C (13 mg) in 1,4-dimethoxygly-
col (5 mL). The mixture was stirred at 60 C for 16 h. The mixture
was cooled and ﬁltered, and the ﬁltrate was concentrated. Prepara-
tive HPLC, followed by column chromatography eluting with 10–
20% 2 M NH3 in MeOH/CH2Cl2, gave 47 as a colourless oil (16 mg,
0.07 mmol, 7% over 3 steps); 1H NMR (500 MHz, CDCl3) d 1.44–
1.52 (1H, m), 1.54–1.59 (1H, m), 1.79–1.91 (4H, m), 1.92–2.03
(1H, m), 2.17–2.20 (1H, m), 2.62–2.65 (1H, m), 2.79 (1H, dd,
J = 13.5, 11.5 Hz), 2.98–3.09 (3H, m), 3.18–3.28 (2H, m), 3.42
(1H), 3.89 (1H), 7.20–7.26 (3H, m), 7.31–7.35 (2H, m); 13C NMR
(126 MHz, CDCl3) d 26.8, 28.0, 37.0, 37.6, 39.5, 39.9, 44.4, 47.2,
48.4, 126.5, 127.0, 128.5, 143.9; LC–MS (ESI+) m/z 231 (M+H);
HRMS m/z calcd for C15H22N2Na (M+Na) 253.1675, found
253.1668.5.1.36. 6-(3-Phenyl-1,9-diazaspiro[5.5]undecan-9-yl)-9H-purine
(48)
A mixture of Et3N (50 lL, 0.35 mmol), 47 (16 mg, 0.07 mmol)
and 6-chloropurine (10 mg, 0.07 mmol) in nBuOH (1 mL) was
heated to 100 C for 4 h. The mixture was cooled to rt and concen-
trated. The resulting solid was washed with MeOH (2 mL) to give
the desired product (3 mg). The washings were concentrated and
puriﬁed by column chromatography, eluting with 10% MeOH/CH2-
Cl2. This material was combined with the previously recovered sol-
ids to give 48 as a white solid (6 mg, 0.17 lmol, 25%). mp = 298 C
(dec); 1H NMR (500 MHz, DMSO-d6) d 1.41 (1H, ddd, J = 13.0, 13.0,
3.5 Hz), 1.50–1.66 (3H, m), 1.69–1.75 (1H, m), 1.77–1.90 (2H, m),
2.03–2.10 (1H, m), 2.59–2.68 (1H, m), 2.81–2.88 (2H, m), 3.87–
4.14 (2H, br m), 4.35–4.77 (2H, br m), 7.19–7.22 (1H, m), 7.27–
7.34 (4H, m), 8.11 (1H, s), 8.20 (1H, s); 13C NMR (126 MHz,
DMSO-d6) d 27.4, 30.3, 36.3, 40.0, 40.3, 43.9, 47.1, 49.8, 119.2,
126.7, 127.6, 128.8, 138.3, 145.0, 151.8, 152.3, 153.5; LC–MS
(ESI+) m/z 349 (M+H); HRMS m/z calcd for C20H25N6 (M+H)
349.2135, found 349.2143.5.1.37. Methyl 2-(((4-allyl-1-benzylpiperidin-4-yl)(benzyl)-
amino)methyl) acrylate (49)
A mixture of methyl 2-(bromomethyl)acrylate (0.49 mL,
4.29 mmol), K2CO3 (790 mg, 5.73 mmol) and 3717 (916 mg,
2.86 mmol) in MeCN (8 mL) was stirred at rt under N2 for 18 h.
The mixture was ﬁltered and the ﬁltrate was concentrated. Gradi-
ent chromatography on a Biotage KPNH column, eluting with 0–8%
EtOAc/cyclohexane, gave 49 as a light yellow oil, (1.14 g,
2.72 mmol, 95%); 1H NMR (500 MHz, CDCl3) d 1.66–1.73 (2H, m),
1.84 (2H, ddd, J = 13.5, 10.0, 4.0 Hz), 2.19–2.27 (2H, m), 2.46 (2H,
dt, J = 7.5, 1.5 Hz), 2.71 (2H, ddd, J = 10.5, 4.5, 4.5 Hz), 3.49–3.57
(4H, m), 3.66 (3H, s), 3.81 (2H, s), 5.07–5.16 (2H, m), 5.73–5.75
(1H, m), 5.92–5.95 (1H, m), 6.04 (1H, ddt, J = 17.5, 10.0, 7.5 Hz),
7.14–7.18 (1H, m), 7.20–7.27 (5H, m), 7.31–7.34 (4H, m); 13C
NMR (126 MHz, CDCl3) d 32.9, 37.5, 49.7, 49.9, 51.5, 53.8, 58.4,
63.2, 117.3, 126.4, 126.4, 126.9, 127.9, 128.1, 128.7, 129.2, 135.2,
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calcd for C27H35N2O2 (M+H) 419.2693, found 419.2699.
5.1.38. Methyl 1,9-dibenzyl-1,9-diazaspiro[5.5]undec-3-ene-3-
carboxylate (50)
A solution of 49 (324 mg, 0.78 mmol) in toluene (8 mL) was
ﬂushed with N2 for 20 min. Dichloro-[1,3-bis(2-methylphenyl)-2-
imidazolidinylidene]-(2-isopropoxyphenylmethylene)-ruthe-
nium(II), (15 mg, 0.026 mmol) was added and the mixture was
heated to 80 C for 16 h. A further 2 portions of ruthenium catalyst
(2  15 mg, 0.026 mmol) were added over the 16 h period. The
reaction was cooled and ﬁltered through basic ion exchange resin,
washing with CH2Cl2. The ﬁltrate was concentrated and puriﬁed by
gradient chromatography on a Biotage KPNH column, eluting with
0–12% EtOAc/cyclohexane, to give 50 as a yellow oil (249 mg,
0.64 mmol, 82%); 1H NMR (500 MHz, CDCl3) d 1.61 (2H, ddd,
J = 13.0, 9.0, 3.0 Hz), 1.91–1.95 (2H, m), 2.17–2.18 (2H, m), 2.42–
2.45 (2H, m), 2.72 (2H, ddd, J = 11.5, 9.0, 3.0 Hz), 3.31–3.33 (2H,
m), 3.58–3.61 (4H, m), 3.69 (3H, s), 7.08 (1H, tt, J = 4.0, 1.5 Hz),
7.23–7.37 (10H, m); 13C NMR (126 MHz, CDCl3) d 31.7, 34.2, 44.2,
48.8, 50.4, 51.5, 51.8, 63.2, 126.6, 127.0, 127.5, 128.2, 128.2,
128.3, 129.3, 137.6, 138.3, 140.6, 166.9; LC–MS (ESI+) m/z 391
(M+H), HRMS m/z calcd for C25H31N2O2 (M+H) 391.2380, found
391.2381.5.1.39. Methyl 9-(9H-purin-6-yl)-1,9-diazaspiro[5.5]undecane-
3-carboxylate (51)
Pd/C (17 mg) and 1 drop of 1 M HCl were added to 50 (177 mg,
0.45 mmol) in MeOH (5 mL) and the ﬂask was evacuated of air and
reﬁlled with 1 atm H2 (3). The mixture was heated to 40 C for
16 h. The mixture was ﬁltered and the ﬁltrate was concentrated.
Ion exchange chromatography on acidic resin eluting with 2 M
NH3 in MeOH gave methyl 1,9-diazaspiro[5.5]undecane-3-carbox-
ylate as a yellow oil (90 mg, 0.42 mmol, 93%). A mixture of Et3N
(0.3 mL, 2.10 mmol), methyl 1,9-diazaspiro[5.5]undecane-3-car-
boxylate (90 mg, 0.42 mmol) and 6-chloropurine (65 mg,
0.42 mmol) in nBuOH (4 mL) was heated to 100 C for 4 h. The mix-
ture was cooled to rt and concentrated. Gradient column chroma-
tography using a Biotage KPNH column, eluting with 0–10% EtOH/
CH2Cl2, gave 51 as a white solid (60 mg, 0.18 mmol, 43%).
mp = 189–192 C; 1H NMR (500 MHz, DMSO-d6) d 1.21–1.26 (1H,
m), 1.37 (1H, ddd, J = 14.0, 10.5, 4.0 Hz), 1.49–1.54 (3H, m), 1.72–
1.83 (3H, m), 2.36 (1H, dddd, J = 13.0, 13.0, 10.0, 10.0 Hz), 2.76
(1H, dd, J = 13.0, 10.0 Hz), 2.90–2.94 (1H, m), 3.60 (3H, s), 3.64–
3.90 (2H, br m), 4.43–4.85 (2H, br m), 8.07 (1H, s), 8.16 (1H, s);
13C NMR (126 MHz, DMSO-d6) d 22.9, 32.0, 35.7, 38.4, 40.6, 42.5,
42.6, 48.8, 51.7, 119.1, 138.2, 151.8, 152.3, 153.5, 174.9; LC–MS
(ESI+) m/z 331 (M+H); HRMS m/z calcd for C16H22N6O2Na (M+Na)
353.1696, found 353.1693.5.1.40. 9-(9H-Purin-6-yl)-1,9-diazaspiro[5.5]undecane-3-
carboxylic acid (52)
A mixture of LiOH (56 mg, 1.45 mmol) and 51 (60 mg,
0.18 mmol) in THF (2 mL), H2O (0.8 mL) and MeOH (1.2 mL) was
stirred at rt for 16 h and then concentrated. The solid was washed
with MeOH (3  3 mL) to give 52 as white solid (15 mg, 0.05 mmol,
27%). mp = 261–263 C; 1H NMR (500 MHz, DMSO-d6) d 1.30 (1H,
ddd, J = 14.0, 12.0, 4.0 Hz), 1.42 (1H, ddd, J = 14.0, 10.0, 4.0 Hz),
1.47–1.57 (3H, m), 1.61–1.71 (1H, m), 1.72–1.83 (2H, m), 2.18
(1H, dddd, J = 8.5, 8.5, 4.5, 4.5 Hz), 2.76 (1H, dd, J = 13.0, 9.0 Hz),
2.89 (1H, dd, J = 13.0, 4.0 Hz), 3.75–4.09 (2H, br m), 4.31–4.75
(2H, br m), 8.07 (1H, s), 8.16 (1H, s); 13C NMR (126 MHz, DMSO-
d6) d 23.3, 32.8, 35.2, 37.3, 40.4, 42.8, 43.2, 49.5, 119.0, 138.4,
151.9, 152.2, 153.5, 176.7; LC–MS (ESI+) m/z 317 (M+H); HRMS
m/z calcd for C15H21N6O2 (M+H) 317.1721, found 317.1722.5.1.41. (9-(9H-Purin-6-yl)-1,9-diazaspiro[5.5]undecan-3-
yl)methanol (53)
1 M LiAlH4 in THF (0.14 mL, 0.14 mmol) was added to a solution
of 51 (6 mg, 0.019) in THF (1 mL) under N2 and the mixture was
stirred at 50 C for 4 h. The mixture was cooled to rt and H2O
(50 lL) and 20% w/w aq NaOH (50 lL) were added. After stirring
for 30 min, H2O (150 lL) was added and the mixture was ﬁltered,
washing the solids with Et2O (3 mL). The ﬁltrate was concentrated
and puriﬁed by ion exchange chromatography on acidic resin, elut-
ing with 2 M NH3 in MeOH, to give 53 as a colourless oil (4 mg,
0.013 mmol, 68%); 1H NMR (500 MHz, DMSO-d6) d 1.11–1.29 (2H,
m), 1.33–1.47 (4H, m), 1.51–1.56 (2H, m), 1.67–1.75 (1H, m) 2.37
(1H, dd, J = 13.0, 10.0 Hz), 2.77 (1H, dd, J = 12.5, 3.5 Hz), 3.22–
3.25 (2H, m), 3.75–3.86 (2H, m), 4.41–4.45 (2H, m), 7.47 (1H, s),
7.87 (1H, s); 13C NMR (126 MHz, DMSO-d6) d 23.5, 31.5, 36.5,
39.9, 40.6, 43.5, 49.3, 64.8, 121.9, 148.4, 148.5, 153.2, one quater-
nary carbon signal not detected; LC–MS (ESI+) m/z 303 (M+H);
HRMS m/z calcd for C15H23N6O (M+H) 303.1928, found 303.1928
5.1.42. 1,9-Dibenzyl-N-methyl-1,9-diazaspiro[5.5]undec-3-ene-
3-carboxamide (54)
A mixture of LiOH (74 mg, 1.93 mmol) and 50 (94 mg,
0.24 mmol) in THF (4 mL), H2O (1 mL) and MeOH (2 mL) was stir-
red at rt for 16 h and then concentrated to give the crude carbox-
ylate salt. The material was dissolved in DMF (2 mL) under N2 and
HATU (119 mg, 0.31 mmol) and EtNiPr2 (0.25 mL, 1.44 mmol) were
added. The mixture was stirred for 30 min at rt 2 M MeNH2 in
MeOH (0.48 mL, 0.96 mmol) was added and the mixture was stir-
red for a further 15 h. H2O (5 mL) was added and the mixture
was extracted with EtOAC (3  5 mL). The extracts were dried
and concentrated, using heptane as an azeotrope to remove traces
of DMF. Gradient column chromatography using a Biotage KPNH
column, eluting with 30–60% EtOAc/cyclohexane, gave 54 as a yel-
low oil (48 mg, 0.12 mmol, 50% over 2 steps); 1H NMR (500 MHz,
CDCl3) d 1.61 (2H, ddd, J = 12.5, 9.0, 3.0 Hz), 1.90–1.92 (2H, m),
2.12–2.14 (2H, m), 2.40–2.43 (2H, m), 2.75 (2H, m), 2.81 (3H, d,
J = 5.0 Hz), 3.28 (2H, s), 3.58–3.60 (4H, m), 5.47 (1H, d, J = 4.5 Hz),
6.70 (1H, dd, J = 5.5, 2.5 Hz), 6.69- 7.36 (10H, m); 13C NMR
(126 MHz, CDCl3) d 26.3, 31.1, 34.2, 44.2, 48.8, 50.4, 51.9, 63.2,
126.7, 127.0, 128.2, 128.3, 128.4, 129.3, 130.2, 130.9, 138.3,
140.5, 167.7; LC–MS (ESI+) m/z 390 (M+H); HRMS m/z calcd for
C25H32N3O (M+H) 390.2540, found 390.2542.
5.1.43. 1,9-Dibenzyl-N,N-dimethyl-1,9-diazaspiro[5.5]undec-3-ene-
3-carboxamide (55)
Prepared as described for 54 starting from 50 and Me2NH (94%
over 2 steps). 1H NMR (500 MHz, CDCl3) d 1.65 (2H, ddd, J = 12.5,
9.0, 3.0 Hz), 1.92–2.03 (2H, m), 2.04–2.08 (2H, m), 2.42–2.45 (2H,
m), 2.68–2.72 (2H, m), 2.90–3.02 (6H, m), 3.23 (2H, s), 3.60 (2H,
s), 3.65 (2H, s), 5.90–5.94 (1H, m), 7.22–7.25 (1H, m), 7.25–7.37
(9H, m); 13C NMR (126 MHz, CDCl3) d 30.1, 34.4, 34.4, 38.6, 45.2,
48.8, 50.4, 51.9, 63.2, 125.2, 126.7, 126.9, 128.2, 128.3, 128.5,
129.3, 132.2, 138.4, 140.6, 171.2; LC–MS (ESI+) m/z 404 (M+H);
HRMS m/z calcd for C26H34N3O (M+H) 404.2696, found 404.2703.
5.1.44. (1,9-Dibenzyl-1,9-diazaspiro[5.5]undec-3-en-3-yl)
(morpholino) methanone (56)
Prepared as described for 54 starting from 50 and morpholine
(49% over 2 steps). 1H NMR (500 MHz, CDCl3) d 1.65 (2H, ddd,
J = 12.5, 9.0, 3.0 Hz), 1.95–1.98 (2H, m), 2.06–2.08 (2H, m), 2.43–
2.45 (2H, m), 2.68–2.73 (2H, m), 3.22 (2H, s), 3.55–3.65 (12H, m),
5.92–5.93 (1H, m), 7.23–7.25 (10H, m); 13C NMR (126 MHz, CDCl3)
d 30.2, 34.4, 45.3, 48.8, 50.5, 51.9, 63.2, 63.2, 66.9, 125.7, 126.8,
127.0, 128.2, 128.4, 128.4, 129.3, 131.5, 138.3, 140.3, 170.2; LC–
MS (ESI+) m/z 446 (M+H); HRMS m/z calcd for C28H36N3O2 (M+H)
446.2802, found 446.2809.
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undecane-3-carboxamide (57)
Pd/C (7 mg) was added to 54 (63 mg, 0.16 mmol) in iPrOH
(5 mL) with 1 drop of 1 M CH3CO2H aq. The ﬂask evacuated of air
and reﬁlled with 1 atm H2 (3). The mixture was heated to 40 C
for 24 h. Catalyst was removed by ﬁltration, fresh catalyst was
added and the reaction was repeated for a further 24 h at 40 C.
The mixture was ﬁltered and the ﬁltrate was concentrated. Ion ex-
change chromatography on acidic resin, eluting with 2 M NH3 in
MeOH gave N-methyl-1,9-diazaspiro[5.5]undecane-3-carboxam-
ide as a yellow oil (36 mg). A mixture of Et3N (0.12 mL, 0.85 mmol),
N-methyl-1,9-diazaspiro[5.5]undecane-3-carboxamide (36 mg,
0.17 mmol) and 6-chloropurine (26 mg, 0.17 mmol) in nBuOH
(1 mL) was heated to 100 C for 4 h. The mixture was cooled to rt
and concentrated. Flash column chromatography eluting with
10% 2 M NH3 in MeOH/CH2Cl2, followed by gradient column chro-
matography using a Biotage KPNH column and eluting with 0–15%
EtOH/CH2Cl2, gave 57 as a colourless oil (13 mg, 0.04 mmol, 23%
over 2 steps); 1H NMR (500 MHz, CD3OD) d 1.37–1.42 (1H, m),
1.59–1.71 (2H, m), 1.76–1.95 (5H, m), 2.35 (1H, dddd, J = 11.0,
11.0, 4.5, 4.5 Hz), 2.74 (3H, s), 2.89 (1H, ddd, J = 13.0, 4.5, 1.5 Hz),
2.99 (1H, dd, J = 13.0, 10.5 Hz), 4.20–4.37 (4H, br m), 8.01 (1H, s),
8.20 (1H, s); 13C NMR (126 MHz, CD3OD) d 23.0, 24.9, 31.0, 33.5,
38.7, 40.8, 41.0, 42.1, 43.9, 49.2, 118.9, 138.0, 151.0, 151.6, 153.7,
176.4; LC–MS (ESI+) m/z 330 (M+H); HRMS m/z calcd for
C16H24N7O (M+H) 330.2037, found 330.2046.
5.1.46. N,N-Dimethyl-9-(9H-purin-6-yl)-1,9-diazaspiro[5.5]
undecane-3-carboxamide (58)
Prepared as described for 57 starting from 55 and 6-chloropu-
rine (24% over 2 steps). 1H NMR (500 MHz, CD3OD) d 1.44–1.52
(1H, m), 1.67–1.88 (5H, m), 1.89–2.04 (2H, m), 2.73–2.80 (1H,
m), 2.94–3.03 (4H, m), 3.06–3.17 (4H, m), 4.10–4.63 (4H, br m),
7.94 (1H, s), 8.33 (1H, s); 13C NMR (126 MHz, CD3OD) d 22.8,
32.0, 34.6, 35.5, 37.2, 38.6, 39.5, 41.0, 42.4, 50.0, 119.6, 136.7,
151.1, 151.5, 153.8, 174.0; LC–MS (ESI+) m/z 344 (M+H); HRMS
m/z calcd for C17H26N7O (M+H) 344.2193, found 344.2192.
5.1.47. (9-(9H-Purin-6-yl)-1,9-diazaspiro[5.5]undecan-3-yl)
(morpholino)methanone (59)
Prepared as described for 57 starting from 56 and 6-chloropu-
rine (32% over 2 steps). 1H NMR (500 MHz, CD3OD) d 1.39–1.48
(1H, m), 1.59–1.73 (2H, m), 1.76–1.81 (1H, m), 1.81–1.95 (4H,
m), 2.77–2.86 (2H, m), 3.01 (1H, dd, J = 13.0, 10.5 Hz), 3.58–3.72
(8H, m), 4.21–4.40 (4H, br m), 8.02 (1H, s), 8.21 (1H, s); 13C NMR
(126 MHz, CD3OD) d 22.7, 30.9, 33., 38.7, 39.0, 40.7, 41.0, 41.9,
45.9, 49.2, 66.4, 66.6, 118.3, 137.7, 150.1, 151.6, 153.6, 173.7;
LC–MS (ESI+) m/z 386 (M+H); HRMS m/z calcd for C19H28N7O2
386.2299, found 386.2307.
6. Declaration of conﬂict of interest
The authors are, or have been, employees of The Institute of
Cancer Research, London which has a commercial interest in PKB,
CHK1 and Aurora kinase inhibitors. Authors who are, or have been,
employed by The Institute of Cancer Research are subject to a ‘Re-
wards to Inventors Scheme’ which may reward contributors to a
programme that is subsequently licensed.
Acknowledgments
This work was supported by the Institute of Cancer Research,
London (studentship to C. E. A.), the Wellcome Trust (studentship
to C. L. C.) and Cancer Research UK [CUK] grant numbers C309/
A8274 and C309/A11566. We acknowledge ‘Reward to Discover’funding from Caliper LifeSciences (I.C.). We thank Dr A. Mirza, Dr
M. Liu and Mr M. Richards for assistance with spectroscopic char-
acterization, and Dr N. Cronin and staff at Diamond Light Source
beamline I04 for their assistance with crystallographic data
collection.
Supplementary data
Supplementary data (IC50 determinations for 12,14 (Table S1); Sin-
gle concentration inhibition of 96 kinases by 41, 42, 45 (Table S2); De-
tails of PKA protein expression, puriﬁcation and crystallisation, and of
data collection and reﬁnement of the crystal structures of 12-PKA, 14-
PKA, 16-PKA, 41-PKA; Experimental methods for the kinase inhibition
assays) associated with this article can be found, in the online version,
at http://dx.doi.org/10.1016/j.bmc.2013.07.021.
References and notes
1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. Science
2002, 298, 1912.
2. Blume-Jensen, P.; Hunter, T. Nature 2001, 411, 355.
3. Hanahan, D.; Weinberg, R. A. Cell 2011, 144, 646.
4. Collins, I.; Workman, P. Curr. Sig. Transduc. Ther. 2006, 1, 13.
5. Zhang, L.; Daly, R. J. Crit. Rev. Oncog. 2012, 17, 233.
6. Faivre, S.; Djelloul, S.; Raymond, E. Semin. Oncol. 2006, 33, 407.
7. Gossage, L.; Eisen, T. Clin. Cancer Res. 2010, 16, 1973.
8. Knight, Z.; Lin, H.; Shokat, K. M. Nat. Rev. Cancer 2010, 10, 130.
9. Morphy, R. J. Med. Chem. 2010, 53, 1413.
10. Traxler, P.; Furet, P. Pharmacol. Ther. 1999, 82, 195.
11. Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. J. Med.
Chem. 2008, 51, 5149.
12. Patel, R. Y.; Doerksen, R. J. J. Proteome Res. 2010, 9, 4433.
13. Caldwell, J. J.; Davies, T. G.; Donald, A.; McHardy, T.; Rowlands, M. G.; Aherne,
G. W.; Hunter, L. K.; Taylor, K.; Ruddle, R.; Raynaud, F. I.; Verdonk, M.;
Workman, P.; Garrett, M. D.; Collins, I. J. Med. Chem. 2008, 51, 2147.
14. McHardy, T.; Caldwell, J. J.; Cheung, K.-M.; Hunter, L. J.; Taylor, K.; Rowlands,
M.; Ruddle, R.; Henley, A.; Brandon, A.; Valenti, M.; Davies, T. G.; Fazal, L.;
Seavers, L.; Raynaud, F. I.; Eccles, S.; Aherne, G. W.; Garrett, M. D.; Collins, I. J.
Med. Chem. 2010, 53, 2239.
15. Freeman-Cook, K. D.; Autry, C.; Borzillo, G.; Gordon, D.; Barbacci-Tobin, E.;
Bernardo, V.; Briere, D.; Clark, T.; Corbett, M.; Jakubczak, J.; Kakar, S.; Knauth,
E.; Lippa, B.; Luzzio, M. J.; Mansour, M.; Martinelli, G.; Marx, M.; Nelson, K.;
Pandit, J.; Rajamohan, F.; Robinson, S.; Subramanyam, C.; Wei, L.; Wythes, M.;
Morris, J. J. Med. Chem. 2010, 53, 4615. Erratum in J. Med. Chem. 2010, 53, 5895.
16. Guimaraes, C. R. W.; Rai, B. K.; Munchhof, M. J.; Liu, S.; Wang, J.; Bhattacharya,
S. K.; Buckbinder, L. J. Chem. Inf. Mod. 2011, 51, 1199.
17. Jenkins, I. D.; Lacrampe, F.; Ripper, J.; Alcaraz, L.; Van Le, P.; Nikolakopoulos, G.;
De Almeida Leone, P.; White, R. H.; Quinn, R. J. J. Org. Chem. 2008, 74, 1304.
18. Meanwell, N. A. Chem. Res. Toxicol. 2011, 24, 1420.
19. Yang, Y.; Engkvist, O.; Llinàs, A.; Chen, H. J. Med. Chem. 2012, 55, 3667.
20. Ishikawa, M.; Hashimoto, Y. J. Med. Chem. 2011, 55, 1534.
21. For recent examples in the patent literature of the incorporation of
unsubstituted diazaspirocycles as peripheral substituent groups in kinase
inhibitors, see: (a) Plettenburg, O.; Schoenau, C.; Loehn, M.; Hachtel, S.;
Pfeiffer-Marek, S.; Mendez-Perez, M.; Kannt, A.; Dedio, J.; Kohlmann, M.;
Schiffer, A.; Begis, G.; Duclos, O.; Jeannot, F. Intl. Pat. Appl. WO2013045413,
2013; Chem. Abstr. 2013, 158, 534920; (b) Hodges, A. J.; Matteucci, M.; Sharpe,
A.; Sun, M.; Wang, X.; Tsui, V. H. US Pat. Appl. US20130079321, 2013; Chem.
Abstr. 2013, 158, 504146; (c) Tong, Y.; Penning, T. D.; Florjancic, A. S.;
Miyashiro, J.; Woods, K. W. US Pat. Appl. US20120220572, 2012; Chem. Abstr.
2012, 157, 438395; (d) Fernandez, J. P.; Gonzalez, S. M.; Hernando, J. I. M.;
Herguea, A. R; Ferreira, M. R. R.; Aparico, C. A. Intl. Pat. Appl. WO2013004984,
2013; Chem. Abstr. 2013, 158, 187521.
22. Pastor, J.; Oyarzabal, J.; Saluste, G.; Alvarez, R. M.; Rivero, V.; Ramo, F.; Cendon,
E.; Blanco-Aparicio, C.; Ajenjo, N.; Cebria, A.; Albarran, M. I.; Cebrian, D.;
Corrionero, A.; Fominaya, J.; Montoya, G.; Mazzorana, M. Bioorg. Med. Chem.
Lett. 2012, 22, 1591.
23. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G. S.; Pandit, J.; Robinson, S.;
Wei, L.; Kozina, E.; Marr, E. S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, E. G.;
Vincent, P.; Troutman, M.; Baker, D.; Rajamohan, F.; Kakar, S.; Tracey Clark, T.;
Morris, J. Bioorg. Med. Chem. Lett. 2008, 18, 3359; (b) Baldino, C. M.; Caserta, J.
L.; Dumas, S. A.; Lee, C.; Flanders, Y. L. US Pat. Appl. US20120270892, 2012;
Chem. Abstr. 2012, 157, 663061.; (c) Zhang, J.; Jin, H.; Tian, Y.; Zhu, Z.; Li, Z.;
Wang, G.; Wan, S.; Ye, L.; You, W.; Wu, S. Chin. Pat. Appl. CN102516263, 2012;
Chem. Abstr. 2012, 157, 165620.
24. Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Hunter, L.-J. K.;
Garrett, M. D.; Rowlands, M. G.; Aherne, G. W.; Davies, T. G.; Berdini, V.;
Woodhead, S. J.; Davis, D.; Seavers, L. C. A.; Wyatt, P. G.; Workman, P.;
McDonald, E. Bioorg. Med. Chem. 2006, 14, 1255.
25. Caldwell, J. J.; Collins, I. Synlett 2006, 2565.
5724 C. E. Allen et al. / Bioorg. Med. Chem. 21 (2013) 5707–572426. Rodriguez, S.; Castillo, E.; Carda, M.; Marco, J. A. Tetrahedron 2002, 58, 1185.
27. Hanessian, S.; van Otterlo, W. A. L.; Nilsson, I.; Bauer, U. Tetrahedron Lett. 2002,
43, 1995.
28. Prusov, E.; Maier, M. E. Tetrahedron 2007, 63, 10469.
29. Padwa, A.; Kuethe, J. T. J. Org. Chem. 1998, 63, 4256.
30. McEleney, K.; Allen, D. P.; Holliday, A. E.; Crudden, C. M. Org. Lett. 2006, 8, 2663.
31. Bujard, M.; Briot, A.; Gouverneur, V.; Mioskowski, C. Tetrahedron Lett. 1999, 40,
8785.
32. Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y. Org.
Lett. 2007, 9, 1589.
33. Schmidt, D. L.; Roberts, C. B.; Reigler, P. F.; Lemanski, M. F.; Schram, E. P. In
Inorganic Syntheses; Wold, A., Ruff, J. K., Eds.; John Wiley & Sons Inc., 2007; pp
47–52.
34. Card, A.; Caldwell, C.; Min, H.; Lokchander, B.; Hualin, X.; Sciabola, S.; Kamath,
A. V.; Clugston, S. L.; Tschantz, W. R.; Leyu, W.; Moshinsky, D. J. J. Biomol.
Screen. 2009, 14, 31.
35. Perrin, D.; Fremaux, C.; Scheer, A. J. Biomol. Screen. 2006, 11, 359.
36. Hopkins, A. L.; Groom, C. R.; Alex, A. Drug Discovery Today 2004, 9, 430.
37. Smyth, L. A.; Collins, I. J. Chem. Biol. 2009, 2, 131.
38. Hidaka, H.; Watanabe, M.; Kobayashi, R. Methods Enzymol. 1991, 201, 328.
39. Posy, S. L.; Hermsmeier, M. A.; Vaccaro, W.; Ott, K.; Todderud, G.; Lippy, J. S.;
Trainor, G. L.; Loughney, D. A.; Johnson, S. R. J. Med. Chem. 2011, 54, 54.40. Bamborough, P.; Brown, M. J.; Christopher, J. A.; Chung, C.; Mellor, G. W. J. Med.
Chem. 2011, 54, 5131.
41. Smyth, L. A.; Matthews, T. P.; Collins, I. Bioorg. Med. Chem. 2011, 19, 3569.
42. Matthews, T. P.; McHardy, T.; Klair, S.; Boxall, K.; Fisher, M.; Cherry, M.; Allen,
C. E.; Addison, G. J.; Ellard, J.; Aherne, G. W.; Westwood, I. M.; van Montfort, R.;
Garrett, M. D.; Reader, J. C.; Collins, I. Bioorg. Med. Chem. Lett. 2010, 20, 4045.
43. IC50 values against speciﬁc kinases were determined from 8–10 point titrations
(n = 1) performed using the microﬂuidic kinase assay (PKA, AurA), or by
titration in the Z’-Lyte assay format (Invitrogen SelectScreen, Life
Technologies Corporation) (CHK1).
44. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.;
Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. J. Med. Chem.
2007, 50, 2293.
45. Davies, T. G.; Verdonk, M. L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C. C. F.;
McHardy, T.; Collins, I.; Garrett, M. D.; Workman, P.; Woodhead, S. J.; Jhoti, H.;
Barford, D. J. Mol. Biol. 2007, 367, 882.
46. Akamine, P.; Madhusudan; Wu, J.; Xuong, N.; Ten Eyck, L. F.; Taylor, S. S. J. Mol.
Biol. 2003, 327, 159.
47. http://www.chemcomp.com/MOE-Molecular_Operating_Environment.htm
(Chemical Computing Group); accessed 15.05.2013.
48. Potterton, L.; McNicholas, S.; Krissinel, E.; Gruber, J.; Cowtan, K.; Emsley, P.;
Murshudov, G. N.; Cohen, S.; Perrakis, A.; Noble, M. Acta Cryst. 2004, D60, 2288.
